US20060194827A1 - 5-Cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds - Google Patents
5-Cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds Download PDFInfo
- Publication number
- US20060194827A1 US20060194827A1 US11/411,676 US41167606A US2006194827A1 US 20060194827 A1 US20060194827 A1 US 20060194827A1 US 41167606 A US41167606 A US 41167606A US 2006194827 A1 US2006194827 A1 US 2006194827A1
- Authority
- US
- United States
- Prior art keywords
- taken together
- bond
- group
- hydrogen
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 169
- 239000002379 progesterone receptor modulator Substances 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 51
- 102000003998 progesterone receptors Human genes 0.000 claims abstract description 43
- 108090000468 progesterone receptors Proteins 0.000 claims abstract description 43
- 230000001404 mediated effect Effects 0.000 claims abstract description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 119
- 229910052731 fluorine Inorganic materials 0.000 claims description 115
- -1 mono-substituted methylidene Chemical group 0.000 claims description 70
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 67
- 239000001257 hydrogen Substances 0.000 claims description 60
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 59
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 50
- 229910052801 chlorine Inorganic materials 0.000 claims description 49
- 229910052794 bromium Inorganic materials 0.000 claims description 42
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 29
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 28
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 24
- 125000001188 haloalkyl group Chemical group 0.000 claims description 21
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 16
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 229940088597 hormone Drugs 0.000 claims description 10
- 239000005556 hormone Substances 0.000 claims description 10
- 229910052740 iodine Inorganic materials 0.000 claims description 10
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 9
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 230000001419 dependent effect Effects 0.000 claims description 8
- 230000035558 fertility Effects 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 230000004913 activation Effects 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 201000010260 leiomyoma Diseases 0.000 claims description 7
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 6
- 201000009273 Endometriosis Diseases 0.000 claims description 5
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 claims description 4
- 206010027514 Metrorrhagia Diseases 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 4
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 3
- 206010060800 Hot flush Diseases 0.000 claims description 3
- 206010027191 meningioma Diseases 0.000 claims description 3
- 230000035935 pregnancy Effects 0.000 claims description 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 29
- 201000011510 cancer Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 abstract description 17
- 239000000203 mixture Substances 0.000 abstract description 16
- 239000005557 antagonist Substances 0.000 abstract description 15
- 239000004031 partial agonist Substances 0.000 abstract description 8
- 239000012190 activator Substances 0.000 abstract description 5
- 230000036961 partial effect Effects 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 82
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 76
- 235000019000 fluorine Nutrition 0.000 description 51
- 238000005160 1H NMR spectroscopy Methods 0.000 description 50
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 50
- 239000011737 fluorine Substances 0.000 description 50
- 238000002360 preparation method Methods 0.000 description 34
- 239000000047 product Substances 0.000 description 30
- 230000000694 effects Effects 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 125000000217 alkyl group Chemical group 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 13
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 239000007787 solid Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 9
- 0 [1*]N1C2=CC=C3C4=C(OC(C5([13*])C([21*])C([19*])([20*])C([18*])C([16*])([17*])C5([14*])[15*])C3=C2C([6*])([7*])C([4*])([5*])C1([2*])[3*])C([8*])=C([9*])C([10*])=C4 Chemical compound [1*]N1C2=CC=C3C4=C(OC(C5([13*])C([21*])C([19*])([20*])C([18*])C([16*])([17*])C5([14*])[15*])C3=C2C([6*])([7*])C([4*])([5*])C1([2*])[3*])C([8*])=C([9*])C([10*])=C4 0.000 description 9
- 229940125878 compound 36 Drugs 0.000 description 9
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 8
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 8
- 229940125961 compound 24 Drugs 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 125000001072 heteroaryl group Chemical group 0.000 description 8
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 7
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 7
- ANKQZFPGUFASCG-UHFFFAOYSA-N dimethyl-(1-methylcyclohex-2-en-1-yl)-phenylsilane Chemical compound C=1C=CC=CC=1[Si](C)(C)C1(C)CCCC=C1 ANKQZFPGUFASCG-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000000583 progesterone congener Substances 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 102000005969 steroid hormone receptors Human genes 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 4
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 4
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000004296 chiral HPLC Methods 0.000 description 4
- 239000006274 endogenous ligand Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 3
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 3
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 3
- JORGUIPRJTXBBG-UHFFFAOYSA-N 7,9-difluoro-2,2,4-trimethyl-5-(3-methylcyclopent-3-en-1-yl)-1,5-dihydrochromeno[3,4-f]quinoline Chemical compound C1C(C)=CCC1C1C2=C3C(C)=CC(C)(C)NC3=CC=C2C2=CC(F)=CC(F)=C2O1 JORGUIPRJTXBBG-UHFFFAOYSA-N 0.000 description 3
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 3
- 229940127007 Compound 39 Drugs 0.000 description 3
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 3
- 108010085012 Steroid Receptors Proteins 0.000 description 3
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940127204 compound 29 Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000006735 epoxidation reaction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000000762 glandular Effects 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 2
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 2
- HNXRLRRQDUXQEE-ALURDMBKSA-N (2s,3r,4s,5r,6r)-2-[[(2r,3s,4r)-4-hydroxy-2-(hydroxymethyl)-3,4-dihydro-2h-pyran-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC=C[C@H]1O HNXRLRRQDUXQEE-ALURDMBKSA-N 0.000 description 2
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 2
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 2
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 2
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 2
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 2
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- PMZDQRJGMBOQBF-UHFFFAOYSA-N 1H-quinolin-4-one Natural products C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 description 2
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 2
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 2
- WKZCVUQQCRLELK-UHFFFAOYSA-N 5-(cyclopenten-1-yl)-7,9-difluoro-2,2,4-trimethyl-1,5-dihydrochromeno[3,4-f]quinoline Chemical compound C12=C3C(C)=CC(C)(C)NC3=CC=C2C2=CC(F)=CC(F)=C2OC1C1=CCCC1 WKZCVUQQCRLELK-UHFFFAOYSA-N 0.000 description 2
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 2
- WYPKYTOTDVWZKP-UHFFFAOYSA-N 5-cyclohex-2-en-1-yl-9-fluoro-2,2,4-trimethyl-1,5-dihydrochromeno[3,4-f]quinoline Chemical compound C12=C3C(C)=CC(C)(C)NC3=CC=C2C2=CC(F)=CC=C2OC1C1CCCC=C1 WYPKYTOTDVWZKP-UHFFFAOYSA-N 0.000 description 2
- DBNRNMZUFWQGHB-UHFFFAOYSA-N 5-cyclopenta-1,4-dien-1-yl-9-fluoro-2,2,4-trimethyl-1,5-dihydrochromeno[3,4-f]quinoline Chemical compound C12=C3C(C)=CC(C)(C)NC3=CC=C2C2=CC(F)=CC=C2OC1C1=CCC=C1 DBNRNMZUFWQGHB-UHFFFAOYSA-N 0.000 description 2
- AUBMWPNTVARGGM-UHFFFAOYSA-N 5h-chromeno[3,4-f]quinoline Chemical compound N1=CC=CC2=C3COC4=CC=CC=C4C3=CC=C21 AUBMWPNTVARGGM-UHFFFAOYSA-N 0.000 description 2
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 2
- JQXQRFQGIMUYIB-UHFFFAOYSA-N 7,9-difluoro-2,2,4-trimethyl-5-(3-methylidenecyclohexyl)-1,5-dihydrochromeno[3,4-f]quinoline Chemical compound C12=C3C(C)=CC(C)(C)NC3=CC=C2C2=CC(F)=CC(F)=C2OC1C1CCCC(=C)C1 JQXQRFQGIMUYIB-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 241000244851 Cymopolia barbata Species 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 101000574060 Homo sapiens Progesterone receptor Proteins 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IOSLINNLJFQMFF-XMMPIXPASA-N [(2R)-1-[[4-[[3-[(4-fluorophenyl)methylsulfanyl]phenoxy]methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound FC1=CC=C(CSC=2C=C(OCC3=CC=C(CN4[C@H](CCC4)CO)C=C3)C=CC=2)C=C1 IOSLINNLJFQMFF-XMMPIXPASA-N 0.000 description 2
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 229940126540 compound 41 Drugs 0.000 description 2
- 229940125936 compound 42 Drugs 0.000 description 2
- 229940125844 compound 46 Drugs 0.000 description 2
- 229940126545 compound 53 Drugs 0.000 description 2
- 229940127113 compound 57 Drugs 0.000 description 2
- 229940125900 compound 59 Drugs 0.000 description 2
- STQUZUMWOPTQQC-UHFFFAOYSA-N cyclohex-2-en-1-yl-dimethyl-phenylsilane Chemical compound C=1C=CC=CC=1[Si](C)(C)C1CCCC=C1 STQUZUMWOPTQQC-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 2
- 239000002834 estrogen receptor modulator Substances 0.000 description 2
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 2
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 2
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001072 progestational effect Effects 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- VSGPVHSTVTXREH-UHFFFAOYSA-N quinolin-4-one Chemical compound C1=CC=C[C]2C(=O)C=CN=C21 VSGPVHSTVTXREH-UHFFFAOYSA-N 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229940095745 sex hormone and modulator of the genital system progesterone receptor modulator Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 108020003113 steroid hormone receptors Proteins 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- ZYNCRIJGELAVOZ-UHFFFAOYSA-N (1,2-dimethylcyclohex-2-en-1-yl)-dimethyl-phenylsilane Chemical compound CC1=CCCCC1(C)[Si](C)(C)C1=CC=CC=C1 ZYNCRIJGELAVOZ-UHFFFAOYSA-N 0.000 description 1
- HMDCQSBLYSXQEO-UHFFFAOYSA-N (1,2-dimethylcyclopent-2-en-1-yl)-dimethyl-phenylsilane Chemical compound CC1=CCCC1(C)[Si](C)(C)C1=CC=CC=C1 HMDCQSBLYSXQEO-UHFFFAOYSA-N 0.000 description 1
- UUTXUDQZAKHACT-UHFFFAOYSA-N (1-ethylcyclohex-2-en-1-yl)-dimethyl-phenylsilane Chemical compound C=1C=CC=CC=1[Si](C)(C)C1(CC)CCCC=C1 UUTXUDQZAKHACT-UHFFFAOYSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- HMLJRGFYVJPVBE-UHFFFAOYSA-N 5,9-dimethoxy-2,2,4-trimethyl-1,5-dihydrochromeno[3,4-f]quinoline Chemical compound N1C(C)(C)C=C(C)C2=C3C(OC)OC4=CC=C(OC)C=C4C3=CC=C21 HMLJRGFYVJPVBE-UHFFFAOYSA-N 0.000 description 1
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
- KBQJGTOEBHOBOD-UHFFFAOYSA-N 5-methoxy-5h-chromeno[3,4-f]quinoline Chemical compound N1=CC=CC2=C3C(OC)OC4=CC=CC=C4C3=CC=C21 KBQJGTOEBHOBOD-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- ZZBOBOFIGYKOFO-UHFFFAOYSA-N 7,9-difluoro-5-methoxy-2,2,4-trimethyl-1,5-dihydrochromeno[3,4-f]quinoline Chemical compound N1C(C)(C)C=C(C)C2=C3C(OC)OC4=C(F)C=C(F)C=C4C3=CC=C21 ZZBOBOFIGYKOFO-UHFFFAOYSA-N 0.000 description 1
- AMBHVSVBNFKSFM-UHFFFAOYSA-N 7,9-difluoro-5-methoxy-2,2-dimethyl-3,5-dihydro-1h-chromeno[3,4-f]quinolin-4-one Chemical compound N1C(C)(C)CC(=O)C2=C3C(OC)OC4=C(F)C=C(F)C=C4C3=CC=C21 AMBHVSVBNFKSFM-UHFFFAOYSA-N 0.000 description 1
- HVJXFELUJXCGMZ-UHFFFAOYSA-N 7-fluoro-5-methoxy-2,2,4-trimethyl-1,5-dihydrochromeno[3,4-f]quinoline Chemical compound N1C(C)(C)C=C(C)C2=C3C(OC)OC4=C(F)C=CC=C4C3=CC=C21 HVJXFELUJXCGMZ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HCAKJNQSSUALNI-UHFFFAOYSA-N 9-fluoro-5,8-dimethoxy-2,2,4-trimethyl-1,5-dihydrochromeno[3,4-f]quinoline Chemical compound N1C(C)(C)C=C(C)C2=C3C(OC)OC4=CC(OC)=C(F)C=C4C3=CC=C21 HCAKJNQSSUALNI-UHFFFAOYSA-N 0.000 description 1
- OJNSFFIREDVKLU-UHFFFAOYSA-N 9-fluoro-5-methoxy-2,2,4-trimethyl-1,5-dihydrochromeno[3,4-f]quinoline Chemical compound N1C(C)(C)C=C(C)C2=C3C(OC)OC4=CC=C(F)C=C4C3=CC=C21 OJNSFFIREDVKLU-UHFFFAOYSA-N 0.000 description 1
- FZHJBQVWZLJFKC-UHFFFAOYSA-N 9-fluoro-5-methoxy-2,2-dimethyl-1,5-dihydrochromeno[3,4-f]quinoline Chemical compound N1C(C)(C)C=CC2=C3C(OC)OC4=CC=C(F)C=C4C3=CC=C21 FZHJBQVWZLJFKC-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010057671 Female sexual dysfunction Diseases 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 101000926939 Homo sapiens Glucocorticoid receptor Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- GRHZLQBPAJAHDM-SPRQWYLLSA-N [(3as,4r,6ar)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] n-[(2s,4s,5s)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound CC1=CC=CC(C)=C1OCC(=O)N[C@H]([C@@H](O)C[C@H](CC=1C=CC=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)CC1=CC=CC=C1 GRHZLQBPAJAHDM-SPRQWYLLSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 239000004015 abortifacient agent Substances 0.000 description 1
- 231100000641 abortifacient agent Toxicity 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 235000017168 chlorine Nutrition 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000008294 cold cream Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- GTBLZUCHKLYPEN-UHFFFAOYSA-N cyclohept-2-en-1-yl-dimethyl-phenylsilane Chemical compound C=1C=CC=CC=1[Si](C)(C)C1CCCCC=C1 GTBLZUCHKLYPEN-UHFFFAOYSA-N 0.000 description 1
- SBEMOANGDSSPJY-UHFFFAOYSA-N cyclohexen-1-yloxy(trimethyl)silane Chemical compound C[Si](C)(C)OC1=CCCCC1 SBEMOANGDSSPJY-UHFFFAOYSA-N 0.000 description 1
- MWNCJSJZTTZUTO-UHFFFAOYSA-N cyclooct-2-en-1-yl-dimethyl-phenylsilane Chemical compound C=1C=CC=CC=1[Si](C)(C)C1CCCCCC=C1 MWNCJSJZTTZUTO-UHFFFAOYSA-N 0.000 description 1
- MFKYHGCODKPZDZ-UHFFFAOYSA-N cyclopent-2-en-1-yl-dimethyl-phenylsilane Chemical compound C=1C=CC=CC=1[Si](C)(C)C1CCC=C1 MFKYHGCODKPZDZ-UHFFFAOYSA-N 0.000 description 1
- RZHQPKYEELJIMK-UHFFFAOYSA-N cyclopenta-2,4-dien-1-yl-dimethyl-phenylsilane Chemical compound C=1C=CC=CC=1[Si](C)(C)C1C=CC=C1 RZHQPKYEELJIMK-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FBCSTMXWOYRJQL-UHFFFAOYSA-N dimethyl-(1-methylcyclopent-2-en-1-yl)-phenylsilane Chemical compound C=1C=CC=CC=1[Si](C)(C)C1(C)CCC=C1 FBCSTMXWOYRJQL-UHFFFAOYSA-N 0.000 description 1
- UKUBBZCGQBKUFY-UHFFFAOYSA-N dimethyl-phenyl-(1,5,5-trimethylcyclohex-2-en-1-yl)silane Chemical compound C1C(C)(C)CC=CC1(C)[Si](C)(C)C1=CC=CC=C1 UKUBBZCGQBKUFY-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 235000013675 iodine Nutrition 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- ZBELDPMWYXDLNY-UHFFFAOYSA-N methyl 9-(4-bromo-2-fluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Br)C=C1F ZBELDPMWYXDLNY-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000044 progesterone antagonist Substances 0.000 description 1
- DNAJDTIOMGISDS-UHFFFAOYSA-N prop-2-enylsilane Chemical compound [SiH3]CC=C DNAJDTIOMGISDS-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- IQQDNMHUOLMLNJ-UHFFFAOYSA-N quinolin-3-ol Chemical compound C1=CC=CC2=CC(O)=CN=C21 IQQDNMHUOLMLNJ-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Definitions
- This invention relates to nonsteroidal 5-cycloalkenyl 5H-chromeno[3,4-j]-quinoline derivatives that may be modulators (i.e., agonists, partial agonists and antagonists) of progesterone receptors and to methods for the making and use of such compounds.
- Progesterone receptor (PR) modulators have been widely used in regulation of female reproduction systems and in treatment of female hormone dependent diseases.
- the effectiveness of known steroidal PR modulators is often tempered by their undesired side-effect profile, particularly during long-term administration.
- the effectiveness of synthetic progestins, such as norgestrel, as female birth control agents must be weighed against the increased risk of breast cancer and heart disease.
- the progesterone antagonist, mifepristone (RU486) if administered for chronic indications, such as uterine fibroids, endometriosis and certain hormone-dependent cancers, could lead to homeostatic imbalances in a patient due to its inherent cross-reactivity as a glucocorticoid receptor (GR) antagonist.
- GR glucocorticoid receptor
- a group of nonsteroidal molecules, which contain a di- or tetra-hydroquinoline ring as core pharmacophore (U.S. Pat. Nos. 5,693,646; 5,693,647 and 5,696,127; PCT Int'l. Publication Nos. WO 99/41256 A1 and WO 99/41257 A1) have been described as steroid receptor modulator compounds.
- the present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by Progesterone Receptor. More particularly, the invention relates to nonsteroidal compounds and compositions which may be high affinity, high specificity agonists, partial agonists (i.e., partial activators and/or tissue-specific activators) and/or antagonists for progesterone receptors. Also provided are methods of making such compounds and pharmaceutical compositions.
- R 1 is selected from the group of hydrogen, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 heteroalkyl, COR 11 , CO 2 R 11 , SO 2 R 11 , and CONR 11 R 12 ;
- R 2 and R 3 each independently is selected from the group of hydrogen, C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl; or
- R 2 and R 3 taken together form a cycloalkyl ring of from three to twelve carbons;
- R 4 through R 7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR 11 , C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, and C 1 -C 4 heteroalkyl; or
- R 6 and R 7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;
- R 8 through R 10 each independently is selected from the group of hydrogen, F, Cl, Br, I, NO 2 , CN, OR 11 , NR 11 R 12 , SR 11 , COR 11 , CO 2 R 11 , CONR 11 R 12 , C 1 -C 8 alkyl, C 1 -C 8 heteroalkyl, C 1 -C 8 haloalkyl, allyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl;
- R 11 and R 12 each is independently selected from the group of hydrogen, C 1 -C 4 alkyl, C 1 -C 4 heteroalkyl, and C 1 -C 4 haloalkyl;
- R 13 is hydrogen
- R 14 through R 20 each independently is selected from the group of hydrogen, F, Cl, Br, OR 11 , C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, and C 1 -C 4 heteroalkyl; or
- R 14 and R 15 taken together are selected from the group of methylidene, carbonyl and thiocarbonyl; or
- R 16 and R 17 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene, ethylidene, carbonyl and thiocarbonyl; or
- R 14 and R 16 taken together form a bond or “—O—” bridge;
- R 16 and R 18 taken together form a bond when n is 1;
- R 21 is hydrogen
- n 0, 1, 2, or 3;
- a 5H-chromeno[3,4-f]quinoline is defined by the following structure:
- alkyl refers to an optionally substituted straight-chain or branched-chain or cyclic-chain alkyl radical having from 1 to about 12 carbon atoms.
- the term also includes substituted straight-chain or branched-chain alkyl radicals having from 1 to about 6 carbon atoms as well as those having from 1 to about 4 carbon atoms.
- alkyl radicals include methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, tert-amyl, pentyl, hexyl, heptyl, octyl and the like.
- alkenyl refers to an optionally substituted straight-chain or branched-chain hydrocarbon radical having one or more carbon-carbon double-bonds and having from 2 to about 18 carbon atoms.
- the term also includes substituted straight-chain or branched-chain alkyl radicals having one or more carbon-carbon double bonds and having from 2 to about 6 carbon atoms as well as those having from 2 to about 4 carbon atoms.
- alkenyl radicals include ethenyl, propenyl, 1,3-butadienyl and the like.
- Metal alone or in combination, refers to ⁇ CH 2 and may be optionally substituted.
- alkynyl refers to an optionally substituted straight-chain or branched-chain hydrocarbon radical having one or more carbon-carbon triple-bonds and having from 2 to about 12 carbon atoms.
- the term also includes substituted straight-chain or branched-chain alkyl radicals having one or more carbon-carbon triple bonds and having from 2 to about 6 carbon atoms as well as those having from 2 to about 4 carbon atoms.
- alkynyl radicals include ethynyl, propynyl, butynyl and the like.
- heteroalkyl refers to alkyl, alkenyl and alkynyl radicals, respectively, as described above, in which one or more skeletal atoms are heteroatoms such as, for example, oxygen, nitrogen, sulfur or combinations thereof.
- heteroalkyl, heteroalkenyl and heteroalkynyl include radicals in which 1 to about 6 skeletal atoms are oxygen, nitrogen, sulfur or combinations thereof, as well as those in which 1 to 4 skeletal atoms are oxygen, nitrogen, sulfur or combinations thereof and those in which 1 to 2 skeletal atoms are oxygen, nitrogen, sulfur or combinations thereof.
- aryl refers to an optionally substituted aromatic ring system.
- aryl includes monocyclic aromatic rings, polyaromatic rings and polycyclic aromatic ring systems containing from to six about twenty carbon atoms.
- aryl also includes monocyclic aromatic rings, polyaromatic rings and polycyclic ring systems containing from six to about 12 carbon atoms, as well as those containing from 6 to about 10 carbon atoms.
- the polyaromatic and polycyclic aromatic rings systems may contain from two to four rings. Examples of aryl radicals include, without limitation, phenyl, biphenyl, naphthyl and anthryl ring systems.
- heteroaryl refers to an optionally substituted aromatic ring system containing from about five to about 20 skeletal ring atoms and having one or more heteroatoms such as, for example, oxygen, nitrogen and sulfur.
- heteroaryl also includes optionally substituted aromatic ring systems having from 5 to about 12 skeletal ring atoms, as well as those having from 5 to about 10 skeletal ring atoms.
- heteroaryl may include five- or six-membered heterocyclic rings, polycyclic heteroaromatic ring systems and polyheteroaromatic ring systems where the ring system has two, three or four rings.
- heterocyclic, polycyclic heteroaromatic and polyheteroaromatic include ring systems containing optionally substituted heteroaromatic rings having more than one heteroatom as described above (e.g., a six membered ring with two nitrogens), including polyheterocyclic ring systems of from two to four rings.
- heteroaryl includes ring systems such as, for example, furanyl, benzofuranyl, chromenyl, pyridyl, pyrrolyl, indolyl, quinolinyl, N-alkyl pyrrolyl, pyridyl-N-oxide, pyrimidyl, pyrazinyl, imidazolyl, pyrazolyl, oxazolyl, benzothiophenyl, purinyl, indolizinyl, thienyl and the like.
- ring systems such as, for example, furanyl, benzofuranyl, chromenyl, pyridyl, pyrrolyl, indolyl, quinolinyl, N-alkyl pyrrolyl, pyridyl-N-oxide, pyrimidyl, pyrazinyl, imidazolyl, pyrazolyl, oxazolyl, benzothiophenyl, pur
- haloalkyl, haloalkenyl, haloalkynyl and haloalkoxy include alkyl, alkenyl, and alkynyl structures, as described above, that are substituted with one or more fluorines, chlorines, bromines or iodines, or with combinations thereof.
- cycloalkyl, aryl, arylalkyl, heteroaryl, alkyl, alkynyl, alkenyl, haloalkyl and heteroalkyl include optionally substituted cycloalkyl, aryl, arylalkyl, heteroaryl, alkyl, alkynyl, alkenyl, haloalkyl and heteroalkyl radicals.
- carrier includes optionally substituted, saturated or unsaturated, three- to eight-membered cyclic structures in which all of the skeletal atoms are carbon.
- heterocycle includes optionally substituted, saturated or unsaturated, three- to eight-membered cyclic structures in which one or more skeletal atoms is oxygen, nitrogen, sulfur, or combinations thereof.
- acyl includes alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl substituents attached to a compound via a carbonyl functionality (e.g., —CO-alkyl, —CO-aryl, —CO-arylalkyl or —CO-heteroarylalkyl, etc.).
- halogen includes F, Cl, Br and I.
- progesterone receptor plays a role.
- Progesterone receptors are known to play a role in conditions including, for example, infertility, contraception, pregnancy maintenance and termination, female hormone deficiency, female sexual dysfunction, dysfunctional uterine bleeding, endometriosis, mood disorder, osteoporosis, and hormone-dependent cancers.
- receptor-selectivity refers to the conditions where a compound displays modulating activity towards one or more particular receptors (e.g., a progesterone receptors) while displaying substantially less or no cross-reactivity towards one or more different receptors (e.g., glucocorticoid receptors).
- a progesterone receptors e.g., a progesterone receptors
- glucocorticoid receptors e.g., glucocorticoid receptors
- selective compounds of the present invention may display modulating activity towards progesterone receptors without displaying substantial cross-reactivity towards another steroid hormone receptors.
- Compounds may be selective for a single receptor, group of similar receptors or multiple receptors.
- tissue-selectivity refers to compounds that display substantial modulating activity in one tissue (e.g., uterine tissue) while displaying lesser modulating activity in at least one other tissue (e.g., breast tissue).
- tissue-selective compounds of the present invention may display substantial modulating activity in uterine and vaginal tissues with lesser modulating activity (partial agonistic or partial antagonistic) in breast tissues relative to the activities of the marketed steroidal progestins in all of the target tissues.
- modulate means affect or influence, for example, the amount, degree or proportion.
- compounds that “modulate” a receptor affect the activity, either positively or negatively, of that receptor.
- the term may be used to refer to the activity of compounds of a receptor as, for example, an agonist, partial agonist or antagonist.
- the term also may be used to refer to the effect that a compound has on a physical and/or physiological condition of an individual.
- certain compounds of the present invention may be used to modulate fertility in an individual. That is, certain compounds of this invention may be used to increase the fertility of an individual, while other compounds of this invention may be used to decrease the fertility of an individual.
- a compound that binds to a receptor and mimics the effect of the native or endogenous ligand is referred to as an “agonist,” while a compound that binds to a receptor and inhibits or has an effect that is opposite that of the native or endogenous ligand is called an “antagonist.”
- “Partial agonists” give an effect of the same type as the native or endogenous ligand, but of a lower magnitude, while “partial antagonists” are incompletely inhibitory or opposite that of the native or endogenous ligand.
- R 1 is selected from the group of hydrogen, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 heteroalkyl, COR 11 , CO 2 R 11 , SO 2 R 11 , and CONR 11 R 12 ;
- R 2 and R 3 each independently is selected from the group of hydrogen, C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl; or
- R 2 and R 3 taken together form a cycloalkyl ring of from three to twelve carbons;
- R 4 through R 7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR 11 , C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, and C 1 -C 4 heteroalkyl; or
- R 6 and R 7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;
- R 8 through R 10 each independently is selected from the group of hydrogen, F, Cl, Br, I, NO 2 , CN, OR 11 , NR 11 R 12 , SR 11 , COR 11 , CO 2 R 11 , CONR 11 R 12 , C 1 -C 8 alkyl, C 1 -C 8 heteroalkyl, C 1 -C 8 haloalkyl, allyl, C 2 -C 8 alkenyl and C 2 -C 8 alkynyl;
- R 11 and R 12 each is independently selected from the group of hydrogen, C 1 -C 4 alkyl, C 1 -C 4 heteroalkyl, and C 1 -C 4 haloalkyl;
- R 13 is hydrogen
- R 14 through R 20 each independently is selected from the group of hydrogen, F, Cl, Br, OR 1 , C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, and C 1 -C 4 heteroalkyl; or
- R 14 and R 15 taken together are selected from the group of methylidene, carbonyl and thiocarbonyl; or
- R 16 and R 17 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene, ethylidene, carbonyl and thiocarbonyl; or
- R 14 and R 16 taken together form a bond or “—O—” bridge;
- R 16 and R 18 taken together form a bond when n is 1;
- R 21 is hydrogen
- n 0, 1, 2, or 3;
- R 2 and R 3 each independently is selected from the group of hydrogen, C 1 -C 4 alkyl, and C 1 -C 4 haloalkyl;
- R 6 is selected from the group of hydrogen, F, Cl, Br, CN, OR 11 , C 1 -C 4 alkyl, and C 1 -C 4 haloalkyl;
- R 8 and R 10 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR 11 , NR 11 R 12 , SR 11 , COR 11 , C 1 -C 4 alkyl, C 1 -C 4 heteroalkyl, C 1 -C 4 haloalkyl, allyl, and C 2 -C 4 alkenyl;
- R 11 and R 12 each is independently selected from the group of hydrogen, C 1 -C 4 alkyl, C 1 -C 4 heteroalkyl, and C 1 -C 4 haloalkyl;
- R 14 , R 15 , R 18 , R 22 , R 23 , R 24 each independently is selected from the group of hydrogen, F, Cl, OR 11 , C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, and C 1 -C 4 heteroalkyl;
- R 22 , R 23 , R 24 together consists of not more than 3 carbon atoms
- R 16 taken together with one of R 14 , R 18 , and R 22 form a bond or “—O—” bridge;
- n 0, 1, 2, or 3
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a progesterone receptor modulator compound according to any one of formulae I through II shown above wherein R 1 through R 24 , and n all have the same definitions as given above.
- the present invention comprises a method of modulating processes mediated by progesterone receptors comprising administering to a patient an effective amount of a compound according to any one of the formulae I through II shown above, wherein R 1 through R 24 , and n all have the same definitions as those given above.
- any of the compounds of the present invention can be synthesized as pharmaceutically acceptable salts for incorporation into various pharmaceutical compositions.
- pharmaceutically acceptable salts include, but are not limited to, hydrochloric, hydrobromic, hydroiodic, hydrofluoric, sulfuric, citric, maleic, acetic, lactic, nicotinic, succinic, oxalic, phosphoric, malonic, salicylic, phenylacetic, stearic, pyridine, ammonium, piperazine, diethylamine, nicotinamide, formic, urea, sodium, potassium, calcium, magnesium, zinc, lithium, cinnamic, methylamino, methanesulfonic, picric, tartaric, triethylamino, dimethylamino, and tris(hydroxymethyl)aminomethane. Additional pharmaceutically acceptable salts are known to those skilled in the art.
- the PR agonist, partial agonist and antagonist compounds of the present invention may be particularly useful for female hormone replacement therapy and as modulators of fertility (e.g., as contraceptives, contragestational agents or abortifacients, in vitro fertilization, pregnancy maintenance), either alone or in conjunction with one or more estrogen receptor modulators.
- the PR modulator compounds of this invention may be also used in the treatment of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flushes, mood disorders, and meningiomas.
- the PR modulator compounds of this invention also may be used in the treatment of various hormone-dependent cancers, including, without limitation, cancers of ovaries, breast, endometrium and prostate.
- the PR modulator compounds of this invention can also be used in treatment of female osteoporosis, either alone or in combination with one or more estrogen receptor modulators.
- a compound with a mixed steroid receptor profile is preferred.
- a PR agonist i.e., progestin
- a compound that is primarily a PR agonist, but also displays some AR and MR modulating activity may prove useful.
- the mixed MR effects would be useful to control water balance in the body, while the AR effects would help to control any acne flare ups that occur.
- the compounds of the present invention can be used in a wide variety of combination therapies to treat the conditions and diseases described above.
- the compounds of the present invention can be used in combination with other hormones and other therapies, including, without limitation, chemotherapeutic agents such as cytostatic and cytotoxic agents, immunological modifiers such as interferons, interleukins, growth hormones and other cytokines, hormone therapies, surgery and radiation therapy.
- PR modulator compounds i.e., agonists, partial agonists and antagonists
- Representative PR modulator compounds include:
- the compounds of the present invention also include racemates, stereoisomers and mixtures of said compounds, including isotopically-labeled and radio-labeled compounds.
- Such isomers can be isolated by standard resolution techniques, including fractional crystallization and chiral column chromatography.
- any of the PR modulator compounds of the present invention can be combined in a mixture with a pharmaceutically acceptable carrier to provide pharmaceutical compositions useful for treating the biological conditions or disorders noted herein in mammalian, and particularly in human patients.
- a pharmaceutically acceptable carrier employed in these pharmaceutical compositions may take a wide variety of forms depending upon the type of administration desired. Suitable administration routes include enteral (e.g., oral), topical, suppository, inhalable and parenteral (e.g., intravenous, intramuscular and subcutaneous).
- compositions in oral liquid dosage forms e.g., suspensions, elixirs and solutions
- typical pharmaceutical media such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like
- carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like will be employed. Due to their ease of administration, tablets and capsules represent a desirable oral dosage form for the pharmaceutical compositions of the present invention.
- the carrier will typically comprise sterile water, although other ingredients that aid in solubility or serve as preservatives may also be included.
- injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like will be employed.
- the compounds of the present invention may be formulated using bland, moisturizing bases, such as ointments or creams.
- suitable ointment bases are petrolatum, petrolatum plus volatile silicones, lanolin and water in oil emulsions such as EucerinTM, available from Beiersdorf (Cincinnati, Ohio).
- suitable cream bases are NiveaTM Cream, available from Beiersdorf (Cincinnati, Ohio), cold cream (USP), Purpose CreamTM, available from Johnson & Johnson (New Brunswick, N.J.), hydrophilic ointment (USP) and LubridermTM, available from Warner-Lambert (Morris Plains, N.J.).
- the pharmaceutical compositions and compounds of the present invention will generally be administered in the form of a dosage unit (e.g., tablet, capsule, etc.).
- the compounds of the present invention generally are administered in a daily dosage of from about 1 ⁇ g/kg of body weight to about 50 mg/kg of body weight.
- the compounds of the present invention are administered in a daily dosage of from about 2 ⁇ g/kg to about 25 mg/kg of body weight.
- the compounds of the present invention are administered in a daily dosage of from about 10 ⁇ g/kg to about 5 mg/kg body weight.
- the particular quantity of pharmaceutical composition according to the present invention administered to a patient will depend upon a number of factors, including, without limitation, the biological activity desired, the condition of the patient, and tolerance for the drug.
- the compounds of this invention also have utility when radio- or isotopically-labeled as ligands for use in assays to determine the presence of PR in a cell background or extract. They are particularly useful due to their ability to selectively activate progesterone receptors, and can therefore be used to determine the presence of such receptors in the presence of other steroid receptors or related intracellular receptors.
- the compounds and pharmaceutical compositions of the present invention may be extremely potent activators of PR.
- the compounds and compositions of the present invention may display 50% maximal activation of PR at a concentration of less than 50 nM.
- Some compounds and compositions of the present invention may display 50% maximal activation of PR at a concentration of less than 20 nM, and some may display such activity at a concentration of less than 10 nM.
- a Lewis acid such as BF 3 Et 2 O (excess) was added dropwise.
- cotransfection assays The function and detailed preparation procedure of the cotransfection assays have been described previously (Pathirana, C. et al., Nonsteroidal Human Progesterone Receptor Modulators from the Marine Alga Cymopolia Barbata. Mol. Pharm. 1995, 47, 630-635). Briefly, the cotransfection assays were carried out in CV-1 cells (African green monkey kidney fibroblasts), which were transiently transfected, by the standard calcium phosphate coprecipitation procedure (Berger, T. S. et al., Interaction of Glucocorticoid Analogues with the Human Glucocorticoid Receptor. J. Steroid Biochem. Mol. Bio.
- progesterone receptor modulator compounds of the present invention The agonist, antagonist and binding activity assay results of selected progesterone receptor modulator compounds of the present invention and the standard reference compounds on PR are shown in Table 1 below. Efficacy is reported as the percent maximal response observed for each compound relative to the reference agonist and antagonist compounds indicated above. Also reported in Table 1 for each compound is its antagonist potency or IC 50 (which is the concentration (nM), required to reduce the maximal response by 50%), and its agonist potency or EC 50 (nM), which is the effective concentration that produced 50% of the maximum response. TABLE 1 Agonist, antagonist and binding activity of progesterone receptor modulator compounds of present invention and the reference agonist compound, progesterone (Prog), and reference antagonist compound, RU486 and ZK299.
- the in vivo activity of selected hPR modulator compounds of the present invention were evaluated utilizing the McPhail assay, according to the following illustrative Examples.
- the Clauberg or McPhail assay is a classic assay utilizing rabbits to measure progestational activity. The reason rabbit is used is because the results observed in rabbit have proved to be a good indicator and predictor of activity in the human.
- immature rabbits are treated initially with estradiol, which induces growth in the uterus. This is followed by treatment with a progestin, which causes a large change in the glandular content of the uterus. It is this change in the glandular component, which is a measure of the progestational activity of a progestin.
- Example provides illustrative pharmaceutical composition formulations:
- Hard gelatin capsules are prepared using the following ingredients: Quantity (mg/capsule) COMPOUND 24 10 Starch, dried 100 Magnesium stearate 10 Total 120 mg The above ingredients are mixed and filled into hard gelatin capsules in 120 mg quantities.
- a tablet is prepared using the ingredients below: Quantity (mg/tablet) COMPOUND 24 10 Cellulose, microcrystalline 200 Silicon dioxide, fumed 10 Stearic acid 10 Total 230 mg
- Tablets each containing 10 mg of active ingredient, are made as follows: Quantity (mg/tablet) COMPOUND 24 10 Starch 45 Cellulose, microcrystalline 35 Polyvinylpyrrolidone (PVP) 4 (as 10% solution in water) Sodium carboxymethyl starch (SCMS) 4.5 Magnesium stearate 0.5 Talc 1.0 Total 100 mg
- the active ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly.
- the solution of PVP is mixed with the resultant powders, which are then passed through a No. 14 mesh U.S. sieve.
- the granules so produced are dried at 50° C. and passed through a No. 18 mesh U.S. sieve.
- the SCMS, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.
- Suppositories each containing 225 mg of active ingredient, may be made as follows: Quantity (mg/suppository) COMPOUND 24 20 Saturated fatty acid glycerides 2,000 Total 2,020 mg
- the active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of normal 2 g capacity and allowed to cool.
- An intravenous formulation may be prepared as follows: Quantity COMPOUND 24 10 mg isotonic saline 1000 mL glycerol 100 mL
- the compound is dissolved in the glycerol and then the solution is slowly diluted with isotonic saline.
- the solution of the above ingredients is then administered intravenously at a rate of 1 mL per minute to a patient.
- the present invention includes any combination of the various species and subgeneric groupings falling within the generic disclosure. This invention therefore includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention relates to methods for modulating processes mediated by progesterone receptor using nonsteroidal compounds and compositions which may be high affinity, high specificity agonists, partial agonists (i.e., partial activators and/or tissue-specific activators) and/or antagonists for progesterone receptors.
Description
- This application is a continuation of and claims priority under 35 U.S.C. §120 to copending allowed U.S. patent application Ser. No.10/684,229, filed Oct. 10, 2003 to Zhi et al., which claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 60/417,975, filed Oct. 11, 2002. The disclosure of each of these applications is incorporated by reference herein in its entirety.
- This invention relates to nonsteroidal 5-cycloalkenyl 5H-chromeno[3,4-j]-quinoline derivatives that may be modulators (i.e., agonists, partial agonists and antagonists) of progesterone receptors and to methods for the making and use of such compounds.
- Progesterone receptor (PR) modulators have been widely used in regulation of female reproduction systems and in treatment of female hormone dependent diseases. The effectiveness of known steroidal PR modulators is often tempered by their undesired side-effect profile, particularly during long-term administration. For example, the effectiveness of synthetic progestins, such as norgestrel, as female birth control agents must be weighed against the increased risk of breast cancer and heart disease. Similarly, the progesterone antagonist, mifepristone (RU486), if administered for chronic indications, such as uterine fibroids, endometriosis and certain hormone-dependent cancers, could lead to homeostatic imbalances in a patient due to its inherent cross-reactivity as a glucocorticoid receptor (GR) antagonist. Accordingly, identification of compounds that have good receptor-selectivity for PR over other steroid hormone receptors as well as good tissue-selectivity (e.g., selectivity for uterine tissue over breast tissue) would be of significant value in the improvement of women's health.
- A group of nonsteroidal molecules, which contain a di- or tetra-hydroquinoline ring as core pharmacophore (U.S. Pat. Nos. 5,693,646; 5,693,647 and 5,696,127; PCT Int'l. Publication Nos. WO 99/41256 A1 and WO 99/41257 A1) have been described as steroid receptor modulator compounds.
- The entire disclosures of the patents, publications and references referred to herein are incorporated by reference herein and are not admitted to be prior art.
- The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by Progesterone Receptor. More particularly, the invention relates to nonsteroidal compounds and compositions which may be high affinity, high specificity agonists, partial agonists (i.e., partial activators and/or tissue-specific activators) and/or antagonists for progesterone receptors. Also provided are methods of making such compounds and pharmaceutical compositions.
-
- R1 is selected from the group of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 heteroalkyl, COR11, CO2R11, SO2R11, and CONR11R12;
- R2 and R3 each independently is selected from the group of hydrogen, C1-C6 alkyl, and C1-C6 haloalkyl; or
- R2 and R3 taken together form a cycloalkyl ring of from three to twelve carbons;
- R4 through R7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR11, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 heteroalkyl; or
- R5 and R7 taken together form a bond; or
- R6 and R7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;
- R8 through R10 each independently is selected from the group of hydrogen, F, Cl, Br, I, NO2, CN, OR11, NR11R12, SR11, COR11, CO2R11, CONR11R12, C1-C8 alkyl, C1-C8 heteroalkyl, C1-C8 haloalkyl, allyl, C2-C8 alkenyl, C2-C8 alkynyl;
- R11 and R12 each is independently selected from the group of hydrogen, C1-C4 alkyl, C1-C4 heteroalkyl, and C1-C4 haloalkyl;
- R13 is hydrogen; or
- R13 and R14 taken together form a bond;
- R14 through R20 each independently is selected from the group of hydrogen, F, Cl, Br, OR11, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 heteroalkyl; or
- R14 and R15 taken together are selected from the group of methylidene, carbonyl and thiocarbonyl; or
- R16 and R17 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene, ethylidene, carbonyl and thiocarbonyl; or
- R14 and R16 taken together form a bond or “—O—” bridge; or
- R16 and R18 taken together form a bond when n is 1; or
- R16 and R19 taken together form a bond when n is 0;
- R21 is hydrogen; or
- R21 and R20 taken together form a bond;
- n is 0, 1, 2, or 3;
- and pharmaceutically acceptable salts and prodrugs thereof.
- As used herein, the following terms are defined with the following meanings, unless explicitly stated otherwise. Furthermore, in an effort to maintain consistency in the naming of compounds of similar structure but differing substituents, the compounds described herein are named according to the following general guidelines. The numbering system for the location of substituents on such compounds is also provided.
-
- The term “alkyl,” alone or in combination, refers to an optionally substituted straight-chain or branched-chain or cyclic-chain alkyl radical having from 1 to about 12 carbon atoms. The term also includes substituted straight-chain or branched-chain alkyl radicals having from 1 to about 6 carbon atoms as well as those having from 1 to about 4 carbon atoms. Examples of alkyl radicals include methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, tert-amyl, pentyl, hexyl, heptyl, octyl and the like.
- The term “alkenyl,” alone or in combination, refers to an optionally substituted straight-chain or branched-chain hydrocarbon radical having one or more carbon-carbon double-bonds and having from 2 to about 18 carbon atoms. The term also includes substituted straight-chain or branched-chain alkyl radicals having one or more carbon-carbon double bonds and having from 2 to about 6 carbon atoms as well as those having from 2 to about 4 carbon atoms. Examples of alkenyl radicals include ethenyl, propenyl, 1,3-butadienyl and the like.
- “Methylidene,” alone or in combination, refers to ═CH2 and may be optionally substituted.
- “Allyl,” alone or in combination, refers to —CH2—CH═CH2 and may be optionally substituted.
- The term “alkynyl,” alone or in combination, refers to an optionally substituted straight-chain or branched-chain hydrocarbon radical having one or more carbon-carbon triple-bonds and having from 2 to about 12 carbon atoms. The term also includes substituted straight-chain or branched-chain alkyl radicals having one or more carbon-carbon triple bonds and having from 2 to about 6 carbon atoms as well as those having from 2 to about 4 carbon atoms. Examples of alkynyl radicals include ethynyl, propynyl, butynyl and the like.
- The term “heteroalkyl,” “heteroalkenyl” and “heteroalkynyl” refer to alkyl, alkenyl and alkynyl radicals, respectively, as described above, in which one or more skeletal atoms are heteroatoms such as, for example, oxygen, nitrogen, sulfur or combinations thereof. The terms heteroalkyl, heteroalkenyl and heteroalkynyl include radicals in which 1 to about 6 skeletal atoms are oxygen, nitrogen, sulfur or combinations thereof, as well as those in which 1 to 4 skeletal atoms are oxygen, nitrogen, sulfur or combinations thereof and those in which 1 to 2 skeletal atoms are oxygen, nitrogen, sulfur or combinations thereof.
- The term “aryl,” alone or in combination, refers to an optionally substituted aromatic ring system. The term aryl includes monocyclic aromatic rings, polyaromatic rings and polycyclic aromatic ring systems containing from to six about twenty carbon atoms. The term aryl also includes monocyclic aromatic rings, polyaromatic rings and polycyclic ring systems containing from six to about 12 carbon atoms, as well as those containing from 6 to about 10 carbon atoms. The polyaromatic and polycyclic aromatic rings systems may contain from two to four rings. Examples of aryl radicals include, without limitation, phenyl, biphenyl, naphthyl and anthryl ring systems.
- The term “heteroaryl” refers to an optionally substituted aromatic ring system containing from about five to about 20 skeletal ring atoms and having one or more heteroatoms such as, for example, oxygen, nitrogen and sulfur. The term heteroaryl also includes optionally substituted aromatic ring systems having from 5 to about 12 skeletal ring atoms, as well as those having from 5 to about 10 skeletal ring atoms. The term heteroaryl may include five- or six-membered heterocyclic rings, polycyclic heteroaromatic ring systems and polyheteroaromatic ring systems where the ring system has two, three or four rings. The terms heterocyclic, polycyclic heteroaromatic and polyheteroaromatic include ring systems containing optionally substituted heteroaromatic rings having more than one heteroatom as described above (e.g., a six membered ring with two nitrogens), including polyheterocyclic ring systems of from two to four rings. The term heteroaryl includes ring systems such as, for example, furanyl, benzofuranyl, chromenyl, pyridyl, pyrrolyl, indolyl, quinolinyl, N-alkyl pyrrolyl, pyridyl-N-oxide, pyrimidyl, pyrazinyl, imidazolyl, pyrazolyl, oxazolyl, benzothiophenyl, purinyl, indolizinyl, thienyl and the like.
- The terms haloalkyl, haloalkenyl, haloalkynyl and haloalkoxy include alkyl, alkenyl, and alkynyl structures, as described above, that are substituted with one or more fluorines, chlorines, bromines or iodines, or with combinations thereof.
- The terms cycloalkyl, aryl, arylalkyl, heteroaryl, alkyl, alkynyl, alkenyl, haloalkyl and heteroalkyl include optionally substituted cycloalkyl, aryl, arylalkyl, heteroaryl, alkyl, alkynyl, alkenyl, haloalkyl and heteroalkyl radicals.
- The term “carbocycle” includes optionally substituted, saturated or unsaturated, three- to eight-membered cyclic structures in which all of the skeletal atoms are carbon.
- The term “heterocycle” includes optionally substituted, saturated or unsaturated, three- to eight-membered cyclic structures in which one or more skeletal atoms is oxygen, nitrogen, sulfur, or combinations thereof.
- The term “acyl” includes alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl substituents attached to a compound via a carbonyl functionality (e.g., —CO-alkyl, —CO-aryl, —CO-arylalkyl or —CO-heteroarylalkyl, etc.).
- The term “halogen” includes F, Cl, Br and I.
- The term “mediate” means affect or influence, frequently indirectly or via some intervening action. Thus, for example, conditions mediated by a progesterone receptor are those in which a progesterone receptor plays a role. Progesterone receptors are known to play a role in conditions including, for example, infertility, contraception, pregnancy maintenance and termination, female hormone deficiency, female sexual dysfunction, dysfunctional uterine bleeding, endometriosis, mood disorder, osteoporosis, and hormone-dependent cancers.
- The term “receptor-selectivity” refers to the conditions where a compound displays modulating activity towards one or more particular receptors (e.g., a progesterone receptors) while displaying substantially less or no cross-reactivity towards one or more different receptors (e.g., glucocorticoid receptors). Thus, for example, selective compounds of the present invention may display modulating activity towards progesterone receptors without displaying substantial cross-reactivity towards another steroid hormone receptors. Compounds may be selective for a single receptor, group of similar receptors or multiple receptors.
- The term “tissue-selectivity” refers to compounds that display substantial modulating activity in one tissue (e.g., uterine tissue) while displaying lesser modulating activity in at least one other tissue (e.g., breast tissue). Thus, for example, tissue-selective compounds of the present invention may display substantial modulating activity in uterine and vaginal tissues with lesser modulating activity (partial agonistic or partial antagonistic) in breast tissues relative to the activities of the marketed steroidal progestins in all of the target tissues.
- The term “modulate” means affect or influence, for example, the amount, degree or proportion. Thus, compounds that “modulate” a receptor affect the activity, either positively or negatively, of that receptor. The term may be used to refer to the activity of compounds of a receptor as, for example, an agonist, partial agonist or antagonist. The term also may be used to refer to the effect that a compound has on a physical and/or physiological condition of an individual. For example, certain compounds of the present invention may be used to modulate fertility in an individual. That is, certain compounds of this invention may be used to increase the fertility of an individual, while other compounds of this invention may be used to decrease the fertility of an individual.
- A compound that binds to a receptor and mimics the effect of the native or endogenous ligand is referred to as an “agonist,” while a compound that binds to a receptor and inhibits or has an effect that is opposite that of the native or endogenous ligand is called an “antagonist.” “Partial agonists” give an effect of the same type as the native or endogenous ligand, but of a lower magnitude, while “partial antagonists” are incompletely inhibitory or opposite that of the native or endogenous ligand.
-
- R1 is selected from the group of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 heteroalkyl, COR11, CO2R11, SO2R11, and CONR11R12;
- R2 and R3 each independently is selected from the group of hydrogen, C1-C6 alkyl, and C1-C6 haloalkyl; or
- R2 and R3 taken together form a cycloalkyl ring of from three to twelve carbons;
- R4 through R7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR11, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 heteroalkyl; or
- R5 and R7 taken together form a bond; or
- R6 and R7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;
- R8 through R10 each independently is selected from the group of hydrogen, F, Cl, Br, I, NO2, CN, OR11, NR11R12, SR11, COR11, CO2R11, CONR11R12, C1-C8 alkyl, C1-C8 heteroalkyl, C1-C8 haloalkyl, allyl, C2-C8 alkenyl and C2-C8 alkynyl;
- R11 and R12 each is independently selected from the group of hydrogen, C1-C4 alkyl, C1-C4 heteroalkyl, and C1-C4 haloalkyl;
- R13 is hydrogen; or
- R13 and R14 taken together form a bond;
- R14 through R20 each independently is selected from the group of hydrogen, F, Cl, Br, OR1, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 heteroalkyl; or
- R14 and R15 taken together are selected from the group of methylidene, carbonyl and thiocarbonyl; or
- R16 and R17 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene, ethylidene, carbonyl and thiocarbonyl; or
- R14 and R16 taken together form a bond or “—O—” bridge; or
- R16 and R18 taken together form a bond when n is 1; or
- R16 and R19 taken together form a bond when n is 0;
- R21 is hydrogen; or
- R21 and R20 taken together form a bond;
- n is 0, 1, 2, or 3;
- and pharmaceutically acceptable salts and prodrugs thereof.
-
- R2 and R3 each independently is selected from the group of hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl;
- R6 is selected from the group of hydrogen, F, Cl, Br, CN, OR11, C1-C4 alkyl, and C1-C4 haloalkyl;
- R8 and R10 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR11, NR11R12, SR11, COR11, C1-C4 alkyl, C1-C4 heteroalkyl, C1-C4 haloalkyl, allyl, and C2-C4 alkenyl;
- R11 and R12 each is independently selected from the group of hydrogen, C1-C4 alkyl, C1-C4 heteroalkyl, and C1-C4 haloalkyl;
- R14, R15, R18, R22, R23, R24 each independently is selected from the group of hydrogen, F, Cl, OR11, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 heteroalkyl;
- R22, R23, R24 together consists of not more than 3 carbon atoms;
- R16 taken together with one of R14, R18, and R22 form a bond or “—O—” bridge;
- n is 0, 1, 2, or 3,
- and pharmaceutically acceptable salts and prodrugs thereof.
- In the following table, the inventors contemplate any combination of the following Markush groups and those described above for the various variables.
TABLE A Table of Markush Groups by Variable Markush Group A Markush Group B Markush Group C Markush Group D R1 H, C1-C4 alkyl, C1-C4 H, C1-C4 alkyl, H and methyl H haloalkyl, C1-C4 COR11, SO2R11 and heteroalkyl, COR11, CONR11R12 CO2R11, SO2R11 and CONR11R12 R2 H, C1-C6 alkyl and C1-C4 alkyl and H and methyl H C1-C6 haloalkyl C1-C4 haloalkyl R2 and R3 taken R2 and R3 taken R2 and R3 taken R2 and R3 taken together form a C3-C12 together form a C4-C10 together form a C6-C8 together form a C5-C6 cycloalkyl ring cycloalkyl ring cycloalkyl ring cycloalkyl ring R3 H, C1-C6 alkyl and C1-C4 alkyl and H and methyl H C1-C6 haloalkyl C1-C4 haloalkyl R4 H, F, Cl, Br, CN, H, F, OR11 and C1-C4 H, F and methyl H OR11, C1-C4 alkyl, alkyl C1-C4 haloalkyl and C1-C4 heteroalkyl R5 H, F, Cl, Br, CN, H, F and C1-C4 H, F and methyl H OR11, C1-C4 alkyl, alkyl C1-C4 haloalkyl, and C1-C4 heteroalkyl R5 and R7 taken together form a bond R6 H, F, Cl, Br, CN, H, F, Cl, Br, CN, H and C1-C4 alkyl methyl OR11, C1-C4 alkyl, OR11, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 haloalkyl and C1-C4 heteroalkyl R6 and R7 taken R6 and R7 taken R6 and R7 taken together form a together form a together form a methylidene, methylidene or methylidene mono-substituted carbonyl methylidene, di- substituted methylidene or carbonyl R7 H, F, Cl, Br, CN, H, F, C1-C4 alkyl H, F and methyl H and F OR11, C1-C4 alkyl, and C1-C4 haloalkyl C1-C4 haloalkyl and C1-C4 heteroalkyl R5 and R7 taken together form a bond R6 and R7 taken R6 and R7 taken R6 and R7 taken R6 and R7 taken together form a together form a together form a together form a methylidene, methylidene or carbonyl methylidene mono-substituted carbonyl methylidene, di- substituted methylidene or carbonyl R8 H, F, Cl, Br, I, H, F, Cl, Br, NO2, H, F, and OR11 H NO2, CN, OR11, CN, OR11, SR11, NR11R12, SR11, C1-C6 alkyl, C1-C6 COR11, CO2R11, heteroalkyl, and C1-C6 CONR11R12, C1-C8 haloalkyl alkyl, C1-C8 heteroalkyl, C1-C8 haloalkyl, allyl, C2-C8 alkenyl and C2-C8 alkynyl R9 H, F, Cl, Br, I, H, F, Cl, Br, NO2, H, F, and OR11 H NO2, CN, OR11, CN, OR11, SR11, NR11R12, SR11, C1-C6 alkyl, C1-C6 COR11, CO2R11, heteroalkyl, and C1-C6 CONR11R12, C1-C8 haloalkyl alkyl, C1-C8 heteroalkyl, C1-C8 haloalkyl, allyl, C2-C8 alkenyl and C2-C8 alkynyl R10 H, F, Cl, Br, I, H, F, Cl, Br, NO2, H, F, and OR11 F NO2, CN, OR11, CN, OR11, SR11, NR11R12, SR11, C1-C6 alkyl, C1-C6 COR11, CO2R11, heteroalkyl and C1-C6 CONR11R12, C1-C8 haloalkyl alkyl, C1-C8 heteroalkyl, C1-C8 haloalkyl, allyl, C2-C8 alkenyl and C2-C8 alkynyl R11 H, C1-C4 alkyl, C1-C4 H and C1-C4 alkyl H and C1-C2 alkyl H heteroalkyl and C1-C4 haloalkyl R12 H, C1-C4 alkyl, C1-C4 H and C1-C4 alkyl H and C1-C2 alkyl H heteroalkyl and C1-C4 haloalkyl R13 H R13 and R14 taken together form a bond R14 H, F, Cl, Br, OR11, H, F, Cl, C1-C4 H, F, C1-C2 alkyl, H C1-C4 alkyl, C1-C4 alkyl and C1-C4 and C1-C2 haloalkyl and C1-C4 haloalkyl haloalkyl heteroalkyl R13 and R14 taken together form a bond R14 and R15 taken R14 and R15 taken R14 and R15 taken together form a together form a together form a methylidene, methylidene or methylidene carbonyl or carbonyl thiocarbonyl R14 and R16 taken R14 and R16 taken R14 and R16 taken together form a together form a together form a bond or “—O—” “—O—” bridge bond bridge R15 H, F, Cl, Br, OR11, H, F, Cl, C1-C4 H and C1-C4 alkyl H C1-C4 alkyl, C1-C4 alkyl and C1-C4 haloalkyl and C1-C4 haloalkyl heteroalkyl R14 and R15 taken R14 and R15 taken R14 and R15 taken together form a together form a together form a methylidene, methylidene or methylidene carbonyl or carbonyl thiocarbonyl R16 H, F, Cl, Br, OR11, H, F, OR11, C1-C4 H, F, and C1-C4 H C1-C4 alkyl, C1-C4 alkyl, and C1-C4 alkyl haloalkyl and C1-C4 haloalkyl heteroalkyl R14 and R16 taken R14 and R16 taken R14 and R16 taken together form a together form a together form a bond or “—O—” “—O—” bridge bond bridge R16 and R17 taken R16 and R17 taken R16 and R17 taken R16 and R17 taken together form a together form a together form a together form a methylidene, methylidene, mono- methylidene or methylidene mono-substituted substituted ethylidene methylidene, di- methylidene, di- substituted substituted methylidene, methylidene, or ethylidene, ethylidene carbonyl or thiocarbonyl R16 and R18 taken together form a bond R16 and R19 taken together form a bond R17 H, F, Cl, Br, OR11, H, F, Cl, C1-C4 H and C1-C2 alkyl methyl C1-C4 alkyl, C1-C4 alkyl and C1-C4 haloalkyl and C1-4 haloalkyl heteroalkyl R16 and R17 taken R16 and R17 taken R16 and R17 taken R16 and R17 taken together form a together form a together form a together form a methylidene, methylidene, mono- methylidene or methylidene mono-substituted substituted ethylidene methylidene, di- methylidene, di- substituted substituted methylidene, methylidene, or ethylidene, ethylidene carbonyl or thiocarbonyl R18 H, F, Cl, Br, OR11, H, F, Cl, C1-C4 H, F and C1-C4 H C1-C4 alkyl, C1-C4 alkyl and C1-C4 alkyl haloalkyl and C1-C4 haloalkyl heteroalkyl R16 and R18 taken together form a bond R19 H, F, Cl, Br, OR11, H, F, Cl, C1-C4 H, F and C1-C4 H C1-C4 alkyl, C1-C4 alkyl and C1-C4 alkyl haloalkyl and C1-C4 haloalkyl heteroalkyl R16 and R19 taken together form a bond R20 H, F, Cl, Br, OR11, H, F, Cl, C1-C4 H, F and C1-C2 H C1-C4 alkyl, C1-C4 alkyl and C1-C4 alkyl haloalkyl and C1-C4 haloalkyl heteroalkyl R21 and R20 taken together form a bond R21 H R21 and R20 taken together form a bond n 0, 1, 2, or 3 0 or 1 1 - In one aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a progesterone receptor modulator compound according to any one of formulae I through II shown above wherein R1 through R24, and n all have the same definitions as given above.
- In another aspect, the present invention comprises a method of modulating processes mediated by progesterone receptors comprising administering to a patient an effective amount of a compound according to any one of the formulae I through II shown above, wherein R1 through R24, and n all have the same definitions as those given above.
- Any of the compounds of the present invention can be synthesized as pharmaceutically acceptable salts for incorporation into various pharmaceutical compositions. As used herein, pharmaceutically acceptable salts include, but are not limited to, hydrochloric, hydrobromic, hydroiodic, hydrofluoric, sulfuric, citric, maleic, acetic, lactic, nicotinic, succinic, oxalic, phosphoric, malonic, salicylic, phenylacetic, stearic, pyridine, ammonium, piperazine, diethylamine, nicotinamide, formic, urea, sodium, potassium, calcium, magnesium, zinc, lithium, cinnamic, methylamino, methanesulfonic, picric, tartaric, triethylamino, dimethylamino, and tris(hydroxymethyl)aminomethane. Additional pharmaceutically acceptable salts are known to those skilled in the art.
- The PR agonist, partial agonist and antagonist compounds of the present invention may be particularly useful for female hormone replacement therapy and as modulators of fertility (e.g., as contraceptives, contragestational agents or abortifacients, in vitro fertilization, pregnancy maintenance), either alone or in conjunction with one or more estrogen receptor modulators. The PR modulator compounds of this invention may be also used in the treatment of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flushes, mood disorders, and meningiomas. The PR modulator compounds of this invention also may be used in the treatment of various hormone-dependent cancers, including, without limitation, cancers of ovaries, breast, endometrium and prostate. The PR modulator compounds of this invention can also be used in treatment of female osteoporosis, either alone or in combination with one or more estrogen receptor modulators.
- It will be understood by those skilled in the art that while the compounds of the present invention will typically be employed as a selective agonists, partial agonists or antagonists, that there may be instances where a compound with a mixed steroid receptor profile is preferred. For example, use of a PR agonist (i.e., progestin) in female contraception often leads to the undesired effects of increased water retention and acne flare ups. In this instance, a compound that is primarily a PR agonist, but also displays some AR and MR modulating activity, may prove useful. Specifically, the mixed MR effects would be useful to control water balance in the body, while the AR effects would help to control any acne flare ups that occur.
- Furthermore, it will be understood by those skilled in the art that the compounds of the present invention, including pharmaceutical compositions and formulations containing these compounds, can be used in a wide variety of combination therapies to treat the conditions and diseases described above. Thus, the compounds of the present invention can be used in combination with other hormones and other therapies, including, without limitation, chemotherapeutic agents such as cytostatic and cytotoxic agents, immunological modifiers such as interferons, interleukins, growth hormones and other cytokines, hormone therapies, surgery and radiation therapy.
- Representative PR modulator compounds (i.e., agonists, partial agonists and antagonists) according to the present invention include:
- (±)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 24);
- (±)-(5l,l′u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 25);
- (+)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 27);
- (−)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 28);
- (±)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 29);
- (±)-(5l,l′u)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 30);
- (+)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 32);
- (−)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 33);
- (±)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 34);
- (±)-(5l,l′u)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 35);
- (+)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 37);
- (−)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 38);
- (±)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 39);
- (±)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5H-chromeno[3,4-f]quinoline (compound 41);
- (±)-(5l,l′u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5H-chromeno[3,4-f]quinoline (compound 42);
- (±)-(5l,l′l)-5-(3-methyl-2-cyclopentenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 44);
- (±)-(5l,l′u)-5-(3-methyl-2-cyclopentenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 45);
- (±)-(5l,l′l)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 47);
- (±)-(5l,l′u)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 48);
- (±)-(5l,l′l)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 50);
- (±)-(5l,l′u)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 51);
- (±)-5-(3-methyl-3-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 52);
- (±)-5-(2-cyclopenta-1,3-dienyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 53);
- (±)-(5l,l′l)-5-(3-ethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 55);
- (±)-(5l,l′u)-5-(3-ethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 56);
- (±)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 58);
- (±)-(5l,l′u)-5-(3-methyl-2-cyclohexenyl)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 59);
- (±)-(5l,l′l)-5-(3-ethyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 61);
- (±)-(5l,l′l)-5-(3-ethylidenecyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 62);
- (±)-(5l,l′l)-5-(3-methyl-3-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 63);
- (±)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 64);
- (±)-(5l,l′u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 65);
- (±)-(5l,l′l)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 67);
- (±)-(5l,l′u)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 68);
- (±)-5-(1-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 69);
- (±)-(5l,l′l)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 71);
- (+)-(5l,l′l)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 73);
- (−)-(5l,l′l)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 74);
- (±)-(5l,l′l)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 75);
- (±)-(5l,l′u)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 76);
- (±)-(5l,l′l)-5-(2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4-methylidene-5H-chromeno[3,4-f]quinoline (compound 77);
- (±)-(5l,l′l)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 79);
- (±)-(5l,l′u)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 80);
- (±)-(5l,l′l)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 81);
- (±)-(5l,l′u)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 82);
- (±)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-1,2,2,4-tetramethyl-5H-chromeno[3,4-f]quinoline (compound 83);
- (±)-5-(2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 84);
- (±)-(5l,l′l)-5-(2,3-dimethyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 85);
- (±)-5-(3-methylidene-cyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 87);
- (±)-(5l,l′u)-5-(3-ethylidenecyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 88);
- (±)-(5l,l′l)-5-(2-cycloheptenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 89);
- (±)-(5l,l′l)-5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 91);
- (±)-(5l,l′u)-5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 92);
- (±)-(5l,l′l)-5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 94);
- (±)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4-methylene-5H-chromeno[3,4-f]quinolin-3-ol (Compound 95);
- (±)-(5l,l′l)-5-(2,3-epoxy-2,3-dimethylcyclopentyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 96);
- (±)-(5l,l′u)-5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 97); and
- (±)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-5H-chromeno[3,4-f]quinolin-4-one (Compound 98).
- The sequence of steps for the general schemes to synthesize the compounds of the present invention is shown below. In each of the Schemes the R groups (e.g., R1 , R2, etc.) correspond to the specific substitution patterns noted in the Examples. However, it will be understood by those skilled in the art that other functionalities disclosed herein at the indicated positions of compounds of formulae I and II also comprise potential substituents for the analogous positions on the structures within the Schemes. In a further aspect, the present invention contains a novel process for the preparation of the compounds of the present invention.
- Scheme I describes the synthesis of the 5-cycloalkenyl analogues 3, 4 and 5. Reduction of lactones 1, which were prepared by the previously disclosed methods (U.S. Pat. Nos. 5,693,646; 5,693,647 and 5,696,127), with DIBAL-H followed by acid catalyzed methylation provides lactal intermediates 2. Treatment of the lactal 2 with a nucleophile, such as a cyclic allylsilane 6, in the presence of a Lewis acid, such as BF3—OEt2, affords the final product 3. Compound of structure 4 may also isolated as a minor product. Methylation of compound 3 with iodomethane in the presence of a base, such as sodium hydride, provides N-methylated product of structure 5.
- The compounds of the present invention also include racemates, stereoisomers and mixtures of said compounds, including isotopically-labeled and radio-labeled compounds. Such isomers can be isolated by standard resolution techniques, including fractional crystallization and chiral column chromatography.
- As noted above, any of the PR modulator compounds of the present invention can be combined in a mixture with a pharmaceutically acceptable carrier to provide pharmaceutical compositions useful for treating the biological conditions or disorders noted herein in mammalian, and particularly in human patients. The particular carrier employed in these pharmaceutical compositions may take a wide variety of forms depending upon the type of administration desired. Suitable administration routes include enteral (e.g., oral), topical, suppository, inhalable and parenteral (e.g., intravenous, intramuscular and subcutaneous).
- In preparing the compositions in oral liquid dosage forms (e.g., suspensions, elixirs and solutions), typical pharmaceutical media, such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like can be employed. Similarly, when preparing oral solid dosage forms (e.g., powders, tablets and capsules), carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like will be employed. Due to their ease of administration, tablets and capsules represent a desirable oral dosage form for the pharmaceutical compositions of the present invention.
- For parenteral administration, the carrier will typically comprise sterile water, although other ingredients that aid in solubility or serve as preservatives may also be included. Furthermore, injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like will be employed.
- For topical administration, the compounds of the present invention may be formulated using bland, moisturizing bases, such as ointments or creams. Examples of suitable ointment bases are petrolatum, petrolatum plus volatile silicones, lanolin and water in oil emulsions such as Eucerin™, available from Beiersdorf (Cincinnati, Ohio). Examples of suitable cream bases are Nivea™ Cream, available from Beiersdorf (Cincinnati, Ohio), cold cream (USP), Purpose Cream™, available from Johnson & Johnson (New Brunswick, N.J.), hydrophilic ointment (USP) and Lubriderm™, available from Warner-Lambert (Morris Plains, N.J.).
- The pharmaceutical compositions and compounds of the present invention will generally be administered in the form of a dosage unit (e.g., tablet, capsule, etc.). The compounds of the present invention generally are administered in a daily dosage of from about 1 μg/kg of body weight to about 50 mg/kg of body weight. Typically, the compounds of the present invention are administered in a daily dosage of from about 2 μg/kg to about 25 mg/kg of body weight. Most often, the compounds of the present invention are administered in a daily dosage of from about 10 μg/kg to about 5 mg/kg body weight. As recognized by those skilled in the art, the particular quantity of pharmaceutical composition according to the present invention administered to a patient will depend upon a number of factors, including, without limitation, the biological activity desired, the condition of the patient, and tolerance for the drug.
- The compounds of this invention also have utility when radio- or isotopically-labeled as ligands for use in assays to determine the presence of PR in a cell background or extract. They are particularly useful due to their ability to selectively activate progesterone receptors, and can therefore be used to determine the presence of such receptors in the presence of other steroid receptors or related intracellular receptors.
- The compounds and pharmaceutical compositions of the present invention may be extremely potent activators of PR. For example, the compounds and compositions of the present invention may display 50% maximal activation of PR at a concentration of less than 50 nM. Some compounds and compositions of the present invention may display 50% maximal activation of PR at a concentration of less than 20 nM, and some may display such activity at a concentration of less than 10 nM.
- The invention will be further illustrated by reference to the following non-limiting Examples.
- Preparation of (±)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline and (±)-(5l,l′u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compounds 24 and 25, Structure 3 of Scheme I, where R8═R9═R13═R15═R18═R19═R20═R21═H, R10═F, R6═R17=methyl, R14/R16=a bond, n=1)
- These compounds were prepared according the following general procedure:
- A mixture of a 5-methoxy-5H-chromeno[3,4-f]quinoline, such as 9-fluoro-2,2,4-trimethyl-5-methoxy-1,2-dihydro-5H-chromeno[3,4-f]quinoline (compound 26, Structure 2 of Scheme I, where R8═R9═H, R10═F, R6=methyl), and a cyclic allylsilane derivative, such as 3-(dimethylphenylsilyl)-3-methyl-1-cyclohexene (Structure 6 of Scheme I, where R17=methyl, R15═R18═R19═R20═R21═H, n=1) (1.0-1.5 equiv.), in dry CH2Cl2 was cooled to −25° C., after which a Lewis acid such as BF3Et2O (excess) was added dropwise. The resulting mixture was stirred at −25° C. for half an hour, then warmed up gradually to 0° C. and quenched with slow addition of aqueous NaHCO3 (concentrated). The reaction mixture was extracted with CH2Cl2 (3×). The extracts were washed with brine, combined, dried over anhydrous Na2SO4, filtered, and concentrated. Purification by flash chromatography (hexane:EtOAc, 9:1) afforded 40-90% of a diastereomeric mixture of the 5-alkenyl products, which then were separated by prep TLC or HPLC.
- Compound 24 was isolated as the major isomer: 1H-NMR (500 MHz, CDCl3) 7.38 (d, J=8.2, 1H), 7.29 (dt, J=9.4, 3.1, 1H), 6.91 (dd, J=8.6, 4.9, 1H), 6.82 (dt, J=8.6, 3.1, 1H), 6.61 (d, J=8.2, 1H), 5.64 (s, 1H), 5.52 (d, J=14.0, 1H), 5.51 (s, 1H), 4.00 (s, 1H), 2.40 (m, 1H), 2.24 (s, 3H), 1.87 (m, 1H), 1.80 (m, 1H), 1.64 (m, 1H), 1.56 (s, 3H), 1.38 (s, 3H), 1.28 (m, 1H), 1.22 (m, 1H), 1.14 (s, 3H), 1.06 (m, 1H).
- Compound 25 was isolated as a minor isomer: 1H NMR (500 MHz, CDCl3) 7.38 (d, J=8.2, 1H), 7.29 (dt, J=9.4, 3.1, 1H), 6.86 (m, 1H), 6.82 (m, 1H), 6.61 (dd, J=8.2,1.8, 1H), 5.63 (d, J=10.1, 1H), 5.47 (s, 1H), 4.89 (s, 1H), 3.99 (s, 1H), 2.38 (m, 1H), 2.17 (s, 3H), 1.88 (m, 2H), 1.77 (m, 1H), 1.69 (m, 2H), 1.54 (s, 3H), 1.48 (m, 1H), 1.38 (d, J=1.8, 3H), 1.20 (d, J=1.2, 3H).
- Preparation of (+)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline and (−)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compounds 27 and 28, Structure 3 of Scheme I, where R8═R9═R13═R15═R18═R19═R20═R21═H, R10═F, R6═R17=methyl, R14/R16=a bond, n=1)
- These compounds were obtained through chiral HPLC separation of compound 24 using a Chiral AD Semiprep Column, 250×20 mm ID, 90% Hexanes/EtOH. Data for compound 27, [α]22 D=+332.3 and compound 28, [α]22 D=−317.1 (EtOH).
- Preparation of (±)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline and (±)-(5l,l′u)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compounds 29 and 30, Structure 3 of Scheme I, where R8═R9═R13═R15═R18═R19═R20═R21═H, R10=hydroxy, R6═R17=methyl, R14/R16=a bond, n=1)
- These compounds were prepared in a similar fashion as that described in Example 1 general procedure from 3-(dimethylphenylsilyl)-3-methyl-1-cyclohexene (Structure 6 of Scheme I, where R17=methyl, R15═R18═R19═R20═R21═H, n=1) and 9-hydroxy-2,2,4-trimethyl-5-methoxy-1,2-dihydro-5H-chromeno[3,4-j]quinoline (Compound 31, Structure 2 of Scheme I, where R8═R9═H, R10=hydroxy, R6=methyl).
- Compound 29 was isolated as the major isomer: 1H NMR (500 MHz, CDCl3) 7.38 (d, J=8.2, 1H), 7.10 (d, J=2.4, 1H), 6.86 (d, J=8.5, 1H), 6.82 (dt, J=8.6, 3.1, 1H), 6.62 (dd, J=8.5, 2.7, 1H), 6.60 (d, J=8.2, 1H), 5.67 (s, 1H), 5.50 (s, 1H), 5.48 (d, J=12.2, 1H), 3.96 (s, 1H), 2.42 (m, 1H), 2.24 (s, 3H), 1.87 (m, 1H), 1.77 (m, 1H), 1.66 (s, 3H), 1.64 (m, 1H), 1.38 (s, 3H), 1.28 (m, 1H), 1.20 (m, 1H), 1.13 (s, 3H), 1.02 (m, 1H).
- Compound 30 was isolated as a minor isomer: 1H NMR (500 MHz, CDCl3) 7.38 (d, J=8.8, 1H), 7.18 (d, J=3.7, 1H), 7.10 (d, J=3.7, 1H), 6.81 (d, J=7.9, 1H), 6.62 (m, 1H), 5.59 (d, J=10.2, 1H), 5.47 (s, 1H), 4.90 (s, 1H), 4.45 (s, 1H), 3.96 (s, 1H), 2.40 (m, 1H), 2.17 (s, 3H), 1.88 (m, 1H), 1.78 (m, 1H), 1.68 (m, 1H), 1.60 (s, 3H), 1.38 (s, 3H), 1.30 (m, 2H), 1.20 (s, 3H), 0.90 (m, 1H).
- Preparation of (+)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline and (−)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compounds 32 and 33, Structure 3 of Scheme I, where R8═R9═R13═R15═R18═R19═R20═R21═H, R10=hydroxy. R6═R17=methyl, R14/R16=a bond, n=1)
- These compounds were obtained through chiral HPLC separation of compound 29 using a Chiral AD Semiprep Column, 250×20 mm ID, 90% Hexanes/EtOH. Data for compound 32, [α]22 D=201.6 and compound 33, [α]22 D=−207.7 (EtOH).
- Preparation of (±)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline, (±)-(5l,l′u)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compounds 34 and 35, Structure 3 of Scheme I, where R9═R13═R15═R18═R19═R20═R21═H, R8═R10=fluorine, R6═R17=methyl, R14/R16=a bond, n=1) and (±)-5-(3-methylidene-cyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compounds 87, Structure 3 of Scheme I, where R9═R13═R14═R15═R18═R19═R20═R21═H, R8═R10=fluorine, R6=methyl, R16/R7=methylidene, n=1)
- These compounds were prepared in a similar fashion as that described in Example 1 general procedure from 3-dimethylphenylsilyl-3-methyl-1-cyclohexene (Structure 6 of Scheme I, where R17=methyl, R15═R18═R19═R20═R21═H, n=1) and 7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5-methoxy-5H-chromeno[3,4-f]quinoline (Compound 36, Structure 5 of Scheme I, where R8═R10=fluorine, R9═H, R=methyl).
- Compound 34 was isolated as a major product: 1H NMR (500 MHz, CDCl3) 7.36 (d, J=8.2, 1H), 7.29 (dt, J=9.4, 1.8, 1H), 6.70 (td, J=9.5, 3.0, 1H), 6.61 (d, J=8.2, 1H), 5.64 (d, J=9.5, 1H), 5.63 (s, 1H), 5.51 (s, 1H), 4.04 (s, 1H), 2.38 (m, 1H), 2.24 (s, 3H), 1.88 (m, 1H), 1.77 (m, 1H), 1.69 (m, 1H), 1.65 (s, 3H), 1.39 (s, 3H), 1.30 (m, 1H), 1.25 (m, 1H), 1.14 (s, 3H), 1.10 (m, 1H).
- Compound 35 was isolated as a miner product: 1H NMR (500 MHz, CDCl3) 7.35 (d, J=8.2, 1H), 7.10 (dt, J=9.8, 2,4, 1H), 6.70 (td, J=10.8, 3.0, 1H), 6.61 (d, J=8.2, 1H), 5.74 (d, J=10.4, 1H), 5.48 (s, 1H), 4.87 (s, 1H), 4.03 (s, 1H), 2.37 (m, 1H), 2.17 (s, 3H), 1.90 (m, 1H), 1.78 (m, 1H), 1.72 (m, 2H), 1.54 (s, 3H), 1.52 (m, 1H), 1.38 (s, 3H), 1.20 (d, J=1.21, 3H).
- Compound 87 was isolated as a 1.6:1 mixture of two diastereomers: 1H NMR (500 MHz, CDCl3) 7.36 (d, J=8.2, 1H), 7.34 (d, J=8.2, 1H), 7.14-7.08 (m, 2H), 6.73-6.67 (m, 2H), 6.60 (d, J=11.3, 1H), 6.58 (d, J=8.2, 1H), 6.10 (d, J=10.1, 1H), 5.72 (d, J=10.1, 1H), 5.64 (d, J=9.2, 1H), 5.62 (s, 1H), 5.51 (s, 1H), 5.42 (s, 1H), 5.39-5.37 (m, 1H), 5.31-5.29 (m, 1H), 4.08-4.02 (m, 1H), 4.01-3.99 (m, 1H), 2.33-2.30 (m, 2H), 2.24 (s, 3H), 2.23 (s, 3H), 2.20-2.00 (m, 4H), 1.99-1.86 (m, 2H), 1.84-1.78 (m, 2H), 1.39 (s, 3H), 1.36 (s, 3H), 1.32-1.22 (m, 4H), 1.14 (s, 3H), 1.13 (s, 3H), 0.98-0.92 (m, 2H).
- Preparation of (+)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline and (−)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compounds 37 and 38, Structure 3 of Scheme I, where R9═R13═R15═R18═R19═R20═R21═H, R8═R10=fluorine, R6═R17=methyl, R14/R16=a bond, n=1)
- These compounds were obtained through chiral HPLC separation of compound 34 using a Chiral AD Semiprep Column, 250×20 mm ID, 90% Hexanes/EtOH. Data for compound 37, [α]22 D=+342.4 and compound 38, [α]22 D=−340.0 (EtOH).
- Preparation of (±)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 39, Structure 3 of Scheme I, where R8═R9═R13═R15═R18═R19═R20═R21═H, R10=methoxy, R6═R17=methyl, R14/R16=a bond, n=1)
- This compound was prepared in a similar fashion as that described in Example 1 general procedure from 3-(dimethylphenylsilyl)-3-methyl-1-cyclohexene (Structure 6 of Scheme I, where R17=methyl, R15═R18═R19═R20═R21═H, n=1) and 5,9-dimethoxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 40, Structure 2 of Scheme I, where R8═R9═H, R10=methoxy, R6=methyl) as a yellow solid: 1H NMR (500 MHz, CDCl3) 7.43 (d, J=7.9, 1H), 7.16 (s, 1H), 6.92 (d, J=8.9, 1H), 6.72 (m, 1H), 6.62 (m, 1H), 5.59 (s, 1H), 5.49 (s, 1H), 5.48 (d, J=9.8, 1H), 3.96 (s, 1H), 3.82 (s, 3H), 2.41 (m, 1H), 2.24 (s, 3H), 1.87 (m, 1H), 1.78 (m, 1H), 1.62 (m, 1H), 1.57 (s, 3H), 1.38 (s, 3H), 1.26 (m, 1H), 1,20 (m, 1H), 1.13 (s, 3H), 1.04 (m, 1H).
- Preparation of (±)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5H-chromeno[3,4-f]quinoline and (±)-(5l,l′u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5H-chromeno[3,4-f]quinoline (Compounds 41 and 42, Structure 3 of Scheme I, where R6═R8═R9═R13═R15═R18═R19═R20═R21═H, R10=fluorine, R17=methyl, R14/R16=a bond, n=1)
- These compounds were prepared in a similar fashion as that described in Example 1 general procedure from 3-(dimethylphenylsilyl)-3-methyl-1-cyclohexene (Structure 6 of Scheme I, where R17=methyl, R15═R18═R19═R20═R21═H, n=1) and 9-fluoro-1,2-dihydro-2,2-dimethyl-5-methoxy-5H-chromeno[3,4-f]quinoline (Compound 43, Structure 5 of Scheme I, where R10=fluorine, R6═R8═R9═H).
- Compound 41 was isolated as a major product: 1H NMR (500 MHz, CDCl3) 7.38 (d, J=8.5, 1H), 7.28 (dd, J=9.8, 3.1, 1H), 6.89 (dd, J=8.5, 4.9, 1H), 6.79 (dt, J=8.6, 2.8, 1H), 6.48 (d, J=8.5, 1H), 6.43 (d, J=10.1, 1H), 5.62 (s, 1H), 5.58 (d, J=10.1, 1H), 5.10 (d, J=9.2, 1H), 3.86 (s, 1H), 2.44 (m, 1H), 1.89 (m, 1H), 1.80 (m, 1H), 1.74 (m, 1H), 1.56 (s, 3H), 1.35 (s, 3H), 1.34 (m, 2H), 1.31 (s, 3H), 1.27 (m, 1H).
- Compound 42 was isolated as a minor product: 1H NMR (500 MHz, CDCl3) 7.31 (d, J=8.5, 1H), 7.28 (dd, J=8.9, 2.1, 1H), 6.87 (dd, J=9.2, 5.2, 1H), 6.80 (dt, J=8.2, 3.1, 1H), 6.49 (d, J=8.2, 1H), 6.36 (d, J=10.1, 1H), 5.55 (d, J=10.4, 1H), 5.10 (d, J=10.1, 1H), 4.88 (s, 1H), 3.88 (s, 1H), 2.44 (m, 1H), 1.90 (m, 1H), 1.72 (m, 1H), 1.60 (m, 2H), 1.56 (s, 3H), 1.52 (m, 2H), 1.35 (s, 3H), 1.32 (s, 3H).
- Preparation of (±)-(5l,l′l)-5-(3-methyl-2-cyclopentenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline and (±)-(5l,l′u)-5-(3-methyl-2-cyclopentenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compounds 44 and 45, Structure 3 of Scheme I, where R8═R9═R13═R15═R19═R20═R21═H, R10═F, R6═R=methyl, R14/R16=a bond, n=0)
- These compounds were prepared in a similar fashion as that described in Example 1 general procedure from 3-(dimethylphenylsilyl)-3-methylcyclopentene (Compound 46, Structure 6 of Scheme I, where R17=methyl, R15═R19═R20═R21═H, n=0) and compound 26 (Structure 2 of Scheme I, where R8═R9═H, R10=fluorine, R6=methyl).
- Compound 44 was isolated as a major product: 1H NMR (500 MHz, CDCl3) 7.38 (d, J=8.5, 1H), 7.29 (dd, J=10.4, 2.8, 1H), 6.86 (dd, J=8.9, 5.2, 1H), 6.79 (dt, J=8.2, 3.1, 1H), 6.60 (d, J=8.2, 1H), 5.61 (d, J=8.8, 1H), 5.52 (s, 1H), 5.34 (s, 1H), 3.99 (s, 1H), 3.00 (m, 1H), 2.24 (s, 3H), 2.29 (m, 1H), 1.63 (m, 2H), 1.55 (s, 3H), 1.38 (s, 3H), 1.14 (s, 3H), 1.06 (m, 1H).
- Compound 45 was isolated as a minor product: 1H NMR (500 MHz, CDCl3) 7.38 (d, J=8.2, 1H), 7.29 (dd, J=8.8, 1.8, 1H), 6.85 (dd, J=8.6, 5.2, 1H), 6.81 (dt, J=8.2, 3.1, 1H), 6.60 (d, J=8.2, 1H), 5.55 (d, J=10.4, 1H), 5.47 (s, 1H), 4.81 (s, 1H), 3.99 (s, 1H), 2.96 (m, 1H), 2.34 (m, 1H), 2.18 (m, 1H), 2.14 (s, 3H), 2.09 (m, 1H), 1.91 (m, 1H), 1.55 (s, 3H), 1.38 (s, 3H), 1.20 (s, 3H).
- Preparation of (±)-(5l,l═l)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline and (±)-(5l,l′u)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compounds 47 and 48, Structure 3 of Scheme I, where R8═R9═R13═R15═R18═R21═H, R10=fluorine, R6═R17═R19═R20=methyl, R14/R16=a bond, n=1)
- These compounds were prepared in a similar fashion as that described in Example 1 general procedure from 3-(dimethylphenylsilyl)-3,5,5-trimethylcyclohexene (Compound 49, Structure 6 of Scheme I, where R17═R19═R20=methyl, R15═R18═R21═H, n=1) and compound 26 (Structure 2 of Scheme I, where R10=fluorine, R6=methyl, R8═R9═H).
- Compound 47 was isolated as a major product: 1H NMR (500 MHz, CDCl3) 7.39 (d, J=8.2, 1H), 7.30 (dd, J=9.8, 3.1, 1H), 6.91 (dd, J=8.9, 4.9, 1H), 6.82 (dt, J=8.6, 3.1, 1H), 6.62 (d, J=8.2, 1H), 5.64 (s, 1H), 5.52 (d, J=9.5, 1H), 5.51 (d, J=1.2, 1H), 4.01 (s, 1H), 2.43 (m, 1H), 2.22 (d, J=1.2, 3H), 1.77 (d, J=17.1, 1H), 1.65 (s, 3H), 1.48 (d, J=17.4, 1H), 1.38 (s, 3H), 1.12 (s, 3H), 0.88 (t, J=12.2, 1H), 0.81 (s, 3H), 0.77 (m, 1H), 0.58 (s, 3H).
- Compound 48 was isolated as a minor isomer: 1H NMR (500 MHz, CDCl3) 7.38 (d, J=8.2, 1 H), 7.28 (dd, J=10.1, 2.7, 1H), 6.87 (dd, J=8.9, 5.2, 1H), 6.82 (dt, J=7.9, 2.8, 1H), 6.62 (d, J=8.2, 1H), 5.56 (d, J=10.1, 1H), 5.50 (s, 1H), 4.94 (s, 1H), 3.99 (s, 1H), 2.42 (m, 1H), 2.17 (s, 3H), 1.83 (s, 1H), 1.56 (m, 4H), 1.38 (s, 3H), 1.22 (s, 3H), 0.97 (s, 3H), 0.58 (s, 3H).
- Preparation of (±)-(5l,l′l)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline, (±)-(5l,l′u)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compounds 50, 51, Structure 3 of Scheme I, where R9═R13═R15═R19═R20═R21═H, R8═R10=fluorine, R6═R17=methyl, R14/R16=a bond, n=0) and (±)-5-(3-methyl-3-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 52, Structure 3 of Scheme I, where R9═R13═R14═R15═R20═R21═H, R8═R10=fluorine, R6═R17=methyl, R16/R19=a bond, n=0)
- These compounds were prepared in a similar fashion as that described in Example 1 general procedure from compound 46 (Structure 6 of Scheme I, where R17=methyl, R15═R19═R20═R21═H, n=0) and compound 36 (Structure 2 of Scheme I, where R9═H, R8═R10=fluorine, R6=methyl).
- Compound 50 was isolated as a major product: 1H NMR (500 MHz, CDCl3) 7.35 (d, J=8.2, 1H), 7.08 (d, J=9.5, 1H), 6.68 (dt, J=9.6, 2.8, 1H), 6.60 (d, J=8.2, 1H), 5.73 (d, J=8.5, 1H), 5.53 (s, 1H), 5.32 (s, 1H), 4.04 (s, 1H), 2.98 (m, 1H), 2.30 (m, 1H), 2.24 (s, 3H),2.12 (m, 1H), 1.66 (s, 3H), 1.65 (m, 1H), 1.38 (s, 3H), 1.14 (s, 3H), 0.88 (m, 1H).
- Compound 51 was isolated as a minor product: 1H NMR (500 MHz, CDCl3) 7.35 (d, J=8.5, 1H), 7.09 (d, J=7.9, 1H), 6.85 (t, 8.5, 1H), 6.60 (d, J=8.2, 1H), 5.68 (d, J=10.4, 1H), 5.48 (s, 1H), 4.79 (s, 1H), 3.99 (s, 1H), 2.95 (m, 1H), 2.36 (m, 1H), 2.18 (m, 1H), 2.14 (s, 3H), 1.94 (m, 1H), 1.65 (s, 3H), 1.38 (s, 3H), 1.20 (s, 3H), 0.88 (m, 1H).
- Compound 52 was isolated as minor products: (syn:anti ratio of 2.2:1) 1H NMR (500 MHz, CDCl3) 7.33 (d, J=8.6, 1H), 7.10 (dt, J=9.8, 2.8, 1H), 6.69 (td, J=9.5, 2.7, 1H), 6.61 (d, J=8.2, 1H), 5.93 (d, J=8.9, 1H), 5.53 (s, 1H), 5.41 (s, 1H), 4.03 (s, 1H), 2.88 (m, 1H), 2.23 (d, J=0.6, 3H), 2.04 (m, 1H), 1.66 (s, 3H), 1.52 (m, 1H), 1.56 (m, 1H), 1.38 (s, 3H), 1.15 (s, 3H), 0.88 (m, 1H).
- Preparation of (±)-5-(2-cyclopenta-1,3-dienyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 53, Structure 3 of Scheme I, where R8═R9═R15═R17═R20═H, R10=fluorine, R6=methyl, R13/R14=a bond, R19/R21 a bond, n=0)
- This compound was prepared in a similar fashion as that described in Example 1 general procedure from 5-(dimethylphenylsilyl)-1,3-cyclopentadiene (Compound 54, Structure 6 of Scheme I, where R15═R17═R20═H, R19/R21=a bond, n=0) and compound 26 (Structure 2 of Scheme I, where R10=fluorine, R6=methyl, R8═R9═H) as a yellow solid: 1H NMR (500 MHz, CDCl3) 7.37 (d, J=8.2, 1H), 7.23 (dd, J=9.5, 2.8, 1H), 6.79 (dd, J=8.6, 4.9, 1H), 6.74 (td, J=8.4, 2.8, 1H), 6.64 (d, J=8.2, 1H), 6.61 (s, 1H), 6.33 (dd, J=5.2, 1.2, 1H), 6.22 (dt, J=5.2, 1.8, 1H), 5.94 (t, J=1.4, 1H), 5.48 (s, 1H), 3.94 (s, 1H), 3.08 (dd, J=23.8, 1.5, 1H), 2.95 (dd, J=23.8, 1.5, 1H), 2.11 (d, J=1.5, 3H), 1.28 (s, 3H), 1.25 (s, 3H).
- Preparation of (±)-(5l,l′l)-5-(3-ethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline and (±)-(5l,l′u)-5-(3-ethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compounds 55 and 56, Structure 3 of Scheme I, where R8═R9═R13═R15═R18═R19═R20═R21═H, R10=fluorine, R6=methyl, R17=ethyl, R14/R16=a bond, n=1)
- These compounds were prepared in a similar fashion as that described in Example 1 general procedure from 3-(dimethylphenylsilyl)-3-ethylcyclohexene (Compound 57, Structure 6 of Scheme I, where R17=ethyl, R15═R18═R19═R20═R21═H, n=1) and compound 26 (Structure 2 of Scheme I, where R10=fluorine, R6=methyl, R8═R9═H).
- Compound 55 was isolated as a major product: 1H NMR (500 MHz, CDCl3) 7.38 (d, J=8.2, 1H), 7.29 (dd, J=9.8, 3.1, 1H), 6.90 (dd, J=8.9, 4.9, 1H), 6.81 (dt, J=8.2, 2.8, 1H), 6.61 (d, J=8.2, 1H), 5.59 (s, 1H), 5.56 (d, J=9.5, 1H), 5.50 (d, J=0.9, 1H), 4.00 (s, 1H), 2.40 (m, 1H), 2.24 (d, J=0.9, 3H), 1.93 (q, J=6.7, 2H), 1.88 (m, 1H), 1.80 (m, 1H), 1.67 (m, 1H), 1.38 (s, 3H), 1.27 (m, 1H), 1.22 (m, 1H), 1.14 (s, 3H), 0.98 (m, 1H), 0.95 (t, J=7.6, 3H).
- Compound 56 was isolated as a minor product: 1H NMR (500 MHz, CDCl3) 7.38 (d, J=7.9, 1H), 7.29 (dd, J=9.8, 3.1, 1H), 6.86 (m, 1H), 6.82 (m, 1H), 6.61 (d, J=8.2, 1H), 5.59 (d, J=10.7, 1H), 5.46 (s, 1H), 4.92 (s, 1H), 3.98 (s, 1H), 2.40 (m, 1H), 2.18 (s, 3H), 1.98 (m, 1H), 1.85 (q, J=7.9, 2H), 1.70 (m, 3H), 1.46 (m, 1H), 1.38 (s, 3H), 1.20 (s, 3H), 0.98 (m, 1H), 0.94 (t, J=7.6, 3H).
- Preparation of (±)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline and (±)-(5l,l′u)-5-(3-methyl-2-cyclohexenyl)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compounds 58 and 59, Structure 3 of Scheme I, where R9═R10═R13═R15═R18═R19═R20═R21═H, R8=fluorine, R6═R17=methyl, R14/R16=a bond, n=1)
- These compounds were prepared in a similar fashion as that described in Example 1 general procedure from 3-(dimethylphenylsilyl)-3-methyl-1-cyclohexene (Structure 6 of Scheme I, where R17=methyl, R15═R18═R19═R20═R21═H, n=1) and 7-fluoro-1,2-dihydro-2,2,4-trimethyl-5-methoxy-5H-chromeno[3,4-f]quinoline (Compound 60, Structure 2 of Scheme I, where R8=fluorine, R6=methyl, R9═R10═H).
- Compound 58 was isolated as a major product: 1H NMR (500 MHz, acetone-d6) 7.54 (d, J=8.2, 1H), 7.50 (d, J=7.6, 1H), 6.95 (m, 2H), 6.75 (d, J=8.2, 1H), 5.64 (s, 1H), 5.63 (s, 1H), 5.62 (d, J=9.5, 1H), 5.54 (s, 1H), 2.36 (m, 1H), 2.23 (s, 3H), 1.90 (m, 1H), 1.78 (m, 1H), 1.70 (m, 1H), 1.62 (s, 3H), 1.37 (s, 3H), 1,29 (m, 2H), 1.13 (s, 3H).
- Compound 59 was isolated as a minor product: 1H NMR (500 MHz, acetone-d6) 7.53 (d, J=8.5, 1H), 7.50 (d, J=6.7, 1H), 6.96 (m, 2H), 6.76 (d, J=8.2, 1H), 5.73 (d, J=10.4, 1H), 5.64 (s, 1H, 5.51 (d, J=1.2, 1H), 4.96 (m, 1H), 2.35 (m, 1H), 2.18 (s, 3H), 1.90 (m, 1H), 1.80 (m, 1H), 1.73 (m, 1H), 1.58 (s, 3H), 1.48 (m, 1H), 1.37 (s, 3H), 1.28 (m, 1H), 1.21 (s, 3H).
- Preparation of (±)-(5l,l′l)-5-(3-ethyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 61, Structure 3 of Scheme I, where R9═R13═R15═R18═R19═R20═R21═H, R8═R10=fluorine, R6=methyl, R17=ethyl, R14/R16=a bond, n=1), (±)-(5l,l′l)-5-(3-ethylidenecyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 62, Structure 3 of Scheme I, where R9═R13═R14═R15═R18═R19═R20═R21═H, R8═R10=fluorine, R6=methyl, R16/R17=ethylidene, n=1) and (±)-(5l,l′u)-5-(3-ethylidenecyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 88, Structure 3 of Scheme I, where R9═R13═R14═R15═R18═R19═R20═R21═H, R8═R10=fluorine, R6=methyl, R16/R17=ethylidene, n=1)
- These compounds were prepared in a similar fashion as that described in Example 1 general procedure from compound 57 (Structure 6 of Scheme I, where R17=ethyl, R15═R18═R19═R20═R21═H, n=1) and compound 36 (Structure 5 of Scheme II, where R8═R10=fluorine, R6=methyl, R9═H).
- Compound 61 was isolated as a major product: 1H NMR (500 MHz, CD3COCD3) 7.54 (d, J=8.2, 1H), 7.31 (dt, J=8.9, 1.8, 1H), 6.83 (td, 9.4, 3.0, 1H), 6.76 (d, J=8.2, 1H), 5.72 (m, 2H), 5.55 (d, J=4.9, 1H), 5.53 (s, 1H), 2.80 (s, 3H), 2.36 (m, 1H), 2.22 (s, 3H), 1.90 (q, J=7.6, 2H), 1.82 (m, 1H), 1.72 (m, 1H), 1.30 (m, 1H), 1.37 (s, 3H), 1.14 (s, 3H), 0.90 (t, J=7.6, 3H).
- Compound 62 was isolated as a minor product: 1H NMR (500 MHz, CD3COCD3) 7.51 (d, J=8.2, 1H), 7.30 (dt, J=10.1, 2.8, 1H), 6.83 (td, 9.6, 2.8, 1H), 6.75 (d, J=8.6, 1H), 5.87 (d, J=10.1, 1H), 5.71 (s, 1H), 5.57 (d, J=1.5, 1H), 5.03 (m, 1H), 2.84 (s, 3H), 2.39 (m, 1H), 2.16 (m, 1H), 2.22 (m, 1H), 1.90 (m, 2H), 1.82 (m, 1H), 1.70 (m, 1H), 1.60 (m, 1H), 1.50 (m, 1H), 1.38 (s, 3H), 1.14 (s, 3H), 0.83 (d, J=7.3, 3H).
- Compound 88 was isolated as a 1:1 mixture of two E/Z-isomers: 1H NMR (500 MHz, acetone-d6) 7.50 (d, J=8.5, 1H), 7.49 (d, J=8.5, 1H), 7.34-7.24 (m, 2H), 6.90-6.80 (m, 2H), 6.64 (d, J=8.5, 1H), 6.61 (d, J=8.5, 1H), 5.86 (d, J=7.9, 1H), 5.80 (d, J=7.9, 1H), 5.49 (s, 1H), 5.36 (s, 1H), 5.34 (s, 1H), 5.22 (s, 1H), 5.16 (s, 1H), 4.79 (s, 1H), 2.44-2.38 (m, 1H), 2.34-2.28 (m, 1H), 2.25 (s, 3H), 2.23 (s, 3H), 1.90-1.74 (m, 6H), 1.68-1.58 (m, 2H), 1.34 (s, 3H), 1.30 (s, 3H), 1.36-1.22 (m, 8H), 1.22 (s, 3H), 1.18 (s, 3H), 0.92-0.84 (m, 6H).
- Preparation of (±)-(5l,l′l)-5-(3-methyl-3-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 63, Structure 3 of Scheme I, where R9═R13═R14═R15═R19═R20═R21═H, R8═R10=fluorine, R6=R17=methyl, R16/R18=a bond, n=1)
- This compound was isolated as a minor product after treatment of compound 34 (Structure 3 of Scheme I, where R9═R13═R15═R18═R19═R20═R21═H, R8═R10=fluorine, R6═R17=methyl, R14/R6=a bond, n=1) with acid: 1H NMR (500 MHz, CDCl3) 7.33 (d, J=8.5, 1H), 7.10 (d, J=10.1, 1H), 6.70 (td, J=10.4, 2,4, 1H), 6.60 (d, J=8.5, 1H), 6.01 (d, J=7.9, 1H), 5.51 (s, 1H), 5.47 (s, 1H), 4.04 (s, 1H), 2.41 (m, 1H), 2.24 (s, 3H), 1.95 (m, 2H), 1.86 (s, 3H), 1.52 (m, 1H), 1.38 (s, 3H), 1.18 (m, 1H), 1.14 (s, 3H), 1.12 (m, 1H), 0.97 (m, 1H).
- Preparation of (±)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline and (±)-(5l,l′u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compounds 64 and 65, Structure 3 of Scheme I, where R8═R13═R15═R18═R19═R20═R21═H, R9=methoxy, R6═R17=methyl, R10=fluorine, R14/R16=a bond, n=1)
- These compounds were prepared in a similar fashion as that described in Example 1 general procedure from 3-(dimethylphenylsilyl)-3-methyl-1-cyclohexene (Structure 6 of Scheme I, where R17=methyl, R15═R18═R19═R20═R21═H, n=1) and 9-fluoro-1,2-dihydro-5,8-dimethoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 66, Structure 2 of Scheme I, where R8═H, R6=methyl, R9=methoxy, R10=fluorine).
- Compound 64 was isolated as a major product: 1H NMR (500 MHz, CD3COCD3) 7.44 (d, J=12.5, 1H), 7.42 (d, J=8.2, 1H), 6.73 (d, J=6.6, 1H), 6.71 (d, J=7.2, 1H), 5.68 (s, 1H), 5.52 (m, 2H), 5.48 (s, 1H), 3.90 (s, 3H), 2.40 (m, 1H), 2.20 (s, 3H), 2.08 (m, 1H), 1.96 (m, 1H), 1.78 (m, 1H), 1.65 (m, 1H), 1.63 (s, 3H), 1.36 (s, 3H), 1.26 (m, 2H), 1.12 (s, 3H).
- Compound 65 was isolated as a minor product: 1H NMR (500 MHz, CD3COCD3) 7.44 (d, J=12.5, 1H), 7.42 (d, J=8.2, 1H), 6.73 (d, J=8.2, 1H), 6.70 (d, J=7.6, 1H), 5.63 (s, 1H), 5.48 (s, 1H), 5.46 (d, J=12.5, 1H), 4.96 (m, 1H), 3.88 (s, 3H), 2.39 (m, 1H), 2.20 (s, 3H), 1.94 (m, 1H), 1.78 (m, 1H), 1.72 (m, 1H), 1.57 (s, 3H), 1.46 (m, 1H), 1.36 (s, 3H), 1.28 (m, 2H), 1.20 (s, 3H).
- Preparation of (±)-(5l,l′l)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline, (±)-(5l,l′u)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compounds 67, 68, Structure 3 of Scheme I, where R9═R13═R15═R17═R19═R20═R21═H, R8═R10=fluorine, R6=methyl, R14/R16=a bond, n=0) and (±)-5-(1-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 69, Structure 3 of Scheme I, where R9═R15═R16═R17═R19═R20═R21═H, R8═R10=fluorine, R6=methyl, R13/R14=a bond, n=0)
- These compounds were prepared in a similar fashion as that described in Example 1 general procedure from 3-(dimethylphenylsilyl)cyclopentene (Compound 70, Structure 6 of Scheme I, where R15═R17═R19═R20═R21═H, n=0) and compound 36 (Structure 2 of Scheme I, where R8═R10=fluorine, R6=methyl, R9═H).
- Compound 61 was isolated as a major product: 1H NMR (500 MHz, CDCl3) 7.37 (d, J=8.2, 1H), 7.10 (dt, J=9.5, 2.7, 1H), 6.71 (td, J=9.5, 3.1, 1H), 6.61 (d, J=8.2, 1H), 5.77 (ddd, 1H), 5.71 (d, J=10.4, 1H), 5.48 (d, J=1.2, 1H), 5.23 (ddd, 1H), 5.53 (s, 1H), 4.02 (s, 1H), 3.01 (m, 1H), 2.46 (m, 1H), 2.28 (m, 1H), 2.07 (m, 1H), 1.95 (m, 1H), 1.39 (s, 3H), 1.28 (m, 2H), 1.19 (s, 3H).
- Compound 62 was isolated as a minor product: 1H NMR (500 MHz, CDCl3) 7.37 (d, J=8.2, 1H), 7.09 (dt, J=9.8, 1.8, 1H), 6.69 (td, J=9.6, 2.8, 1H), 6.61 (d, J=8.6, 1H), 5.78 (m, 1H), 5.77 (s, 1H), 5.75 (s, 1H), 5.74 (m, 1H), 5.53 (s, 1H), 4.05 (s, 1H), 2.93 (m, 1H), 2.38 (m, 1H), 2.24 (d, J=0.9, 3H), 1.63 (m, 2H), 1.39 (s, 3H), 1.15 (s, 3H).
- Compound 63 was isolated as a minor product: 1H NMR (500 MHz, CDCl3) 7.31 (d, J=8.6, 1H), 7.04 (m, 1H), 6.66 (m, 1H), 6.61 (d, J=8.6, 1H), 6.31 (m, 1H), 5.49 (m, 1H), 5.16 (q, J=1.8, 1H), 3.96 (s, 1H), 2.52 (m, 1H), 2.35 (m, 1H), 2.18 (s, 3H), 1.85 (m, 1H), 1.78 (m, 1H), 1.29 (d, J=20.8, 3H), 1.16 (m, 2H), 1.15 (s, 3H).
- Preparation of (±)-(5l,l′l)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 71, Structure 3 of Scheme I, where R9═R13═R19═R20═R21═H, R8═R10=fluorine, R6═R15═R17=methyl, R14/R16=a bond, n=0)
- This compound was prepared in a similar fashion as that described in Example 1 general procedure from 3-(dimethylphenylsilyl)-2,3-dimethylcyclopentene (Compound 72, Structure 6 of Scheme I, where R19═R20═R21═H, R15═R17=methyl, n=0) and compound 36 (Structure 2 of Scheme I, where R8═R10=fluorine, R6=methyl, R9═H) as a yellow solid: 1H NMR (500 MHz, CDCl3) 7.32 (d, J=8.2, 1H), 7.09 (dt, J=9.8, 2.7, 1H), 6.69 (td, J=10.8, 2.8, 1H), 6.59 (d, J=7.5, 1H), 5.92 (d, J=8.2, 1H), 5.53 (s, 1H), 4.01 (s, 1H), 2.86 (m, 1H), 2.29 (m, 1H), 2.22 (s, 3H), 2.00 (m, 1H), 1.57 (s, 3H), 1.55 (s, 3H), 1.50 (m, 1H), 1.38 (s, 3H), 1.14 (s, 3H).
- Preparation of (+)-(5l,l′l)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline and (−)-(5l,l′l)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compounds 73 and 74, Structure 3 of Scheme I, where R9═R13═R19═R20═R21═H, R8═R10=fluorine, R6═R15═R17=methyl, R14/R16=a bond, n=0)
- These compounds were obtained through chiral HPLC separation of compound 71 using a Chiral AD Semiprep Column, 250×20 mm ID, 90% Hexanes/EtOH. Data for compound 73, [α]22 D=+256.7 and compound 74, [α]22 D=−263.8 (EtOH).
- Preparation of (±)-(5l,l′l)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline, (±)-(5l,l′u)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compounds 75 and 76, Structure 3 of Scheme I, where R9═R15═R16═R17═R18═R19═R20═R21═H, R8═R10=fluorine, R6=methyl, R13/R14=a bond, n=1) and (±)-(5l,l′l)-5-(2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4-methylidene-5H-chromeno[3,4-f]quinoline (Compound 77, Structure 4 of Scheme I, where R4═R17═H, X═O)
- These compounds were prepared in a similar fashion as that described in Example 1 general procedure from 3-(dimethylphenylsilyl)cyclohexene (Compound 78, Structure 6 of Scheme I, where R15═R17═R18═R19═R20═R21═H, n=1) and compound 36 (Structure 2 of Scheme I, where R8═R10=fluorine, R6=methyl, R9═H).
- Compound 75 was isolated as a major product: 1H NMR (500 MHz, CDCl3) 7.35 (d, J=8.2, 1H), 7.08 (td, J=9.8, 1.8, 1H), 6.69 (dt, J=9.5, 3.0, 1H), 6.61 (d, J=8.2, 1H), 5.90 (d, J=11.0, 1H), 5.76 (m, 1H), 5.68 (d, J=9.5, 1H), 5.52 (d, J=1.2, 1H), 4.06 (s, 1H), 2.41 (m, 1H), 2.24 (d, J=1, 3H), 1.94 (m, 2H), 1.66 (m, 2H), 1.39 (s, 3H), 1.28 (m, 1H), 1.25 (m, 1H), 1.14 (s, 3H).
- Compound 76 was isolated as a minor product: 1H NMR (500 MHz, CDCl3) 7.35 (d, J=8.2, 1H), 7.10 (td, J=9.8, 1.8, 1H), 6.70 (dt, J=8.6, 2.7, 1H), 6.60 (d, J=8.2, 1H), 5.78 (d, J=10.4, 1H), 5.68 (m, 1H), 5.48 (s, 1H), 5.12 (d, J=7.9, 1H), 4.04 (s, 1H), 2.41 (m, 1H), 2.20 (s, 3H), 1.98 (m, 2H), 1.78 (m, 2H), 1.38 (s, 3H), 1,28 (m, 1H), 1.25 (m, 1H), 1.18 (s, 3H).
- Compound 77 was isolated as a minor product: 1H NMR (500 MHz, CDCl3) 7.31 (d, J=8.6, 1H), 7.08 (m, 1H), 6.68 (m, 1H), 6.43 (d, J=8.2, 1H), 5.85 (m, 1H), 5.73 (m, 1H), 5.40 (s, 1H), 5.18 (s, 1H), 4.04 (s, 1H), 2.33 (d, J=11.3, 1H), 2.27 (d, J=12.2, 1H), 2.00 (m, 1H), 1.93 (m, 1H), 1.68 (m, 1H), 1.94 (m, 2H), 1.34 (s, 3H), 1.18 (m, 1H), 1.14 (s, 3H), 0.86 (m, 2H).
- Preparation of (±)-(5l,l′l)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline and (±)-(5l,l′u)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compounds 79 and 80, Structure 3 of Scheme I, where R8═R9═R13═R16═R17═R18═R19═R20═R21═H, R10=fluorine, R6=methyl, R14/R15=methylidene, n=1) (±)-(5l,l′l)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline and (±)-(5l,l′u)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compounds 81 and 82, Structure 3 of Scheme I, where R8═R9═R13═R16═R17═R18═R19═R20═R21═H, R10=fluorine, R6=methyl, R14/R15=carbonyl, n=1)
- Compounds 81 and 82 were prepared in a similar fashion as that described in Example 1 general procedure from 1-(trimethylsilyloxy)cyclohexene and compound 26 (Structure 2 of Scheme I, where R10=fluorine, R6=methyl, R8═R9═H).
- Compound 81 was isolated as a major product: 1H NMR (500 MHz, CDCl3) 7.36 (d, J=8.6, 1H), 7.30 (dd, J=13.4, 4.6, 1H), 6.81 (d, J=7.0, 1H), 6.80 (d, J=8.2, 1H), 6.61 (d, J=8.5, 1H), 6.58 (d, J=9.2, 1H), 5.49 (s, 1H), 3.99 (s, 1H), 2.84 (m, 1H), 2.45 (m, 1H), 2.28 (s, 3H), 2.24 (m, 1H), 1.99 (m, 1H), 1.68 (m, 2H), 1.40 (m, 2H), 1.37 (s, 3H), 1.11 (s, 3H).
- Compound 82 was isolated as a minor product: 1H NMR (500 MHz, CDCl3) 7.36 (d, J=8.6, 1H), 7.30 (dd, J=7.3, 1H), 6.81 (d, J=8.8, 1H), 6.79 (d, J=7.6, 1H), 6.59 (d, J=8.2, 1H), 6.44 (d, J=5.8, 1H), 5.49 (s, 1H), 3.99 (s, 1H), 2.59 (m, 1H), 2.35 (m, 1H), 2.26 (s, 3H), 2.20 (m, 1H), 1.90 (m, 2H), 1.80 (m, 1H), 1.70 (m, 2H), 1.45 (m, 2H), 1.37 (s, 3H), 1.12 (s, 3H).
- The title compounds 79 and 80 were prepared by using a Wittig procedure from compounds 81 and 82. Data for compound 79: 1H NMR (500 MHz, CDCl3) 7.38 (d, J=8.2, 1H), 7.31 (dd, J=7.6, 2.8, 1H), 6.78 (m, 1H), 6.80 (d, J=8.2, 1H), 6.61 (m, 1H), 6.02 (d, J=10.1, 1H), 5.52 (s, 1H), 4.83 (s, 1H), 4.71 (s, 1H), 4.02 (s, 1H), 2.50 (m, 1H), 2.42 (s, 3H), 2.30 (m, 1H), 2.07 (m, 1H), 1.60 m, m1H), 1.45 (m, 2H), 1.39 (s, 3H), 1.30 (m, 1H), 1.18 (m, 1H), 1.12 (s, 3H, 1.08 (m, 1H). Data for compound 80: 1H NMR (500 MHz, CDCl3) 7.38 (d, J=8.8, 1H), 7.34 (m, 1H), 6.78 (m, 1H), 6.86 (m, 1H), 6.54 (d, J=8.9, 1H), 6.01 (d, J=9.2, 1H), 5.47 (s, 1H), 4.41 (s, 1H), 4.10 (s, 1H), 3.98 (s, 1H), 2.56 (m, 1H), 2.30 (s, 3H), 2.04 (m, 3H), 1.76 (m, 1H), 1.68 (m, 1H), 1.58 (m, 1H), 1.36 (s, 3H), 1.30 (m, 2H), 1.09 (s, 3H).
- Preparation of (±)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-1,2,2,4-tetramethyl-5H-chromeno[3,4-f]quinoline (Compound 83, Structure 5 of Scheme I)
- This compound was prepared by methylation of compound 39 (Structure 3 of Scheme I, where R8═R9═R13═R15═R18═R19═R20═R21═H, R10=methoxy, R6═R7=methyl, R14/R16=a bond, n=1) as a yellow solid: 1H NMR (500 MHz, CDCl3) 7.56 (d, J=8.5, 1H), 7.28 (d, J=2.1, 1H), 6.92 (d, J=8.9, 1H), 6.75 (m, 2H), 5.69 (s, 1H), 5.54 (s, 1H), 5.50 (d, J=9.8, 1H), 3.83 (s, 3H), 2.89 (s, 3 H), 2.41 (m, 1H), 2.26 (s, 3H), 1.87 (m, 1H), 1.77 (m, 1H), 1.66 (s, 3H), 1.62 (m, 1H), 1.51 (s, 3H), 1.28 (m, 2H), 1.18 (m, 1H), 0.96 (s, 3H).
- Preparation of (±)-5-(2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compounds 84, Structure 3 of Scheme I, where R8═R9═R13═R15═R17═R18═R19═R20═R21═H, R10═F, R6=methyl, R14/R16=a bond, n=1)
- This compound was prepared in a similar fashion as that described in Example 1 general procedure from 3-(dimethylphenylsilyl)cyclohexene (Compound 78, Structure 6 of Scheme I, where R15═R17═R18═R19═R20═R21═H, n=1) and compound 26 (Structure 2 of Scheme I, where R10=fluorine, R6=methyl, R8═R9═H) as a 1:1 mixture of two diastereomers: 1H NMR (500 MHz, CDCl3) 7.38 (d, J=8.2, 1H), 7.38 (d, J=8.2, 1H), 7.30 (t, J=2.8, 1H), 7.28 (t, J=2.8, 1H), 6.90-6.85 (m, 2H), 6.85-6.80 (m, 2H), 6.61 (d, J=8.2, 1H), 6.61 (d, J=8.2, 1H), 5.91 (d, J=10.1, 1H), 5.78-5.71 (m, 1H), 5.67 (d, J=10.1, 1H), 5.70-5.64 (m, 1H), 5.57 (d, J=9.8, 1H), 5.51 (s, 1H), 5.47 (s, 1H), 5.18-5.14 (m, 1H), 4.02-3.98 (m, 2H), 2.46-2.38 (m, 1H), 2.24 (s, 3H), 2.20 (s, 3H), 2.04-1.90 (m, 4H), 1.80-1.70 (m, 3H), 1.68-1.62 (m, 1H), 1.48-1.42 (m, 1H), 1.49 (s, 3H), 1.47 (s, 3H), 1.32-1.22 (m, 2H), 1.16 (s, 3H), 1.14 (s, 3H), 0.98-0.92 (m, 2H).
- Preparation of (±)-(5l,l′l)-5-(2,3-dimethyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 85, Structure 3 of Scheme I, where R9═R13═R18═R19═R20═R21═H, R8═R10=fluorine, R6═R15═R17=methyl, R14/R16=a bond, n=1)
- This compound was prepared in a similar fashion as that described in Example 1 general procedure from 3-(dimethylphenylsilyl)-2,3-dimethylcyclohexene (Compound 86, Structure 6 of Scheme I, where R18═R19═R20═R21═H, R15═R17=methyl, n=1) and Compound 36 (Structure 2 of Scheme I, where R8═R10=fluorine, R9═H, R6=methyl) as a yellow solid: 1H NMR (500 MHz, acetone-d6) 7.50 (d, J=8.2, 1H), 7.30 (dt, J=10.1, 1.8, 1H), 6.84 (td, J=9.8, 2.8, 1H), 6.75 (d, J=8.2, 1H), 6.01 (d, J=6.4, 1H), 5.72 (s, 1H), 5.55 (d, 1.2, 1H), 2.30 (m, 1H), 2.22 (s, 3H), 2.00-1.8 (m, 3H), 1.59 (s, 3H), 1.50 (s, 3H), 1.46-1.40 (m, 1H), 1.37 (s, 3H), 1.36-1.26 (m, 3H), 1.15 (s, 3H).
- Preparation of (±)-(5l,l′l)-5-(2-cycloheptenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 89, Structure 3 of Scheme I, where R9═R13═R15═R17═R18═R19═R20═R21═H, R8═R10=fluorine, R6=methyl, R14/R16=a bond, n=2)
- This compound was prepared in a similar fashion as that described in Example 1 general procedure from 3-(dimethylphenylsilyl)cycloheptene (Compound 90, Structure 6 of Scheme I, where R 15 ═R 17 ═R 18 ═R 19 ═R 20 ═R 21 ═H, n=2) and Compound 36 (Structure 2 of Scheme I, where R8═R10=fluorine, R9═H, R6=methyl) as a yellow solid: 1H NMR (500 MHz, CDCl3) 7.36 (d, J=8.6, 1H), 7.10 (d, J=9.8, 1H), 6.68 (ddd, J=9.5, 2.8, 2.8, 1H), 6.61 (d, J=8.2, 1H), 6.03 (d, J=11.6, 1H), 5.84-5.76 (m, 1H), 5.80 (d, J=10.1, 1H), 5.52 (s, 1H), 4.10 (s, 1H), 2.47 (m, 1H), 2.24 (s, 3H), 2.12-2.04 (m, 2H), 1.94-1.84 (m, 1H), 1.78-1.84 (m, 1H), 1.44-1.44 (m, 1H), 1.38 (s, 3H), 1.24-1.18 (m, 2H), 1.11 (s, 3H), 0.98-0.92 (m, 1H).
- Preparation of (±)-(5l,l′l)-5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3 4-f]quinoline and (±)-(5l,l′u)-5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compounds 91 and 92, Structure 3 of Scheme I, where R9═R13═R15═R17═R19═R20 ═R21═H, R8═R10═fluorine, R6=methyl, R14/R16=a bond, n=3)
- These compounds were prepared in a similar fashion as that described in Example 1 general procedure from 3-(dimethylphenylsilyl)cyclooctene (Compound 93, Structure 6 of Scheme I, where R13═R15═R17═R18═R19═R20═R21═H, n=3) and Compound 36 (Structure 2 of Scheme I, where R8═R10=fluorine, R9═H, R6=methyl) as a yellow solid: Compound 91 1H NMR (500 MHz, CDCl3) 7.36 (d, J=8.6, 1H), 7.10 (d, J=9.8, 1H), 6.68 (ddd, J=9.5, 2.8, 2.8, 1H), 6.58 (d, J=8.2, 1H), 5.87 (d, J=9.5, 1H), 5.74-5.66 (m, 1H), 5.56 (t, J=10.1, 1H), 5.52 (s, 1H), 4.03 (s, 1H), 2.90-2.80 (m, 1H), 2.26 (s, 3H), 1.88-1.80 (m, 1H), 1.54-1.46 (m, 2H), 1.40-1.32 (m, 2H), 1.23-1.17 (m, 2H), 1.38 (s, 3H), 1.24-1.18 (m, 2H), 1.19 (s, 3H), 1.07-0.98 (m, 1H); Compound 92 1H NMR (500 MHz, CDCl3) 7.33 (d, J=8.5, 1H), 7.11 (d, J=9.8, 1H), 6.71 (ddd, J=9.5, 2.8, 2.8, 1H), 6.61 (d, J=8.2, 1H), 5.87 (d, J=8.8, 1H), 5.54 (s, 1H), 5.54-5.48 (m, 1H), 5.23 (t, J=10.4, 1H), 4.01 (s, 1H), 2.88-2.80 (m, 1H), 2.26 (s, 3H), 1.96-1.88 (m, 1H), 1.84-1.70 (m, 2H), 1.54-1.46 (m, 2H), 1.45-1.38 (m, 1H), 1.38 (s, 3H), 1.36-1.26-1.17 (m, 2H), 1.20-1.00 (m, 2H), 1.10 (s, 3H).
- Preparation of (±)-(5l,l′l)-5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 94, Structure 3 of Scheme I, where R9═R13═R15═R18═R19═R20═R21═H, R8═R10=fluorine, R6═R17=methyl, R14/R16═—O—, n=1) and (±)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4-methylene-5H-chromeno[3,4-f]quinolin-3-ol (Compound 95, Structure 4 of Scheme I, where R4=hydroxy, R17=methyl, X═O)
- These compounds were prepared by epoxidation of Compound 34 (Structure 3 of Scheme I, where R9═R13═R15═R18═R19═R20═R21═H, R8═R10=fluorine, R6═R17=methyl, R14/R16=a bond, n=1) according to a standard procedure as yellow solids: Compound 94, 1H NMR (500 MHz, acetone-d6) 7.54 (d, J=8.5, 1H), 7.35 (ddd, J=9.2,1.8, 1.8, 1H), 6.89 (ddd, J=9.5, 2.8, 2.8, 1H), 6.76 (d, J=8.5, 1H), 6.02 (d, J=10.1, 1H), 5.74 (s, 1H), 5.54 (s, 1H), 3.15 (d, J=2.1, 1H), 2.28 (d, J=0.6, 3H), 2.16-2.00 (m, 1H), 1.72-1.66 (m, 2H), 1.37 (s, 3H), 1.40-1.28 (m, 1H), 1.28 (s, 3H), 1.11 (s, 3H), 1.08-0.93 (m, 2H), 0.84-0.76 (m, 1H; Compound 95, 1H NMR (500 MHz, acetone-d6) 7.48 (d, J=8.5, 1H), 7.28 (ddd, J=9.2,1.8, 1.8, 1H), 6.83 (ddd, J=9.5, 2.8, 2.8, 1H), 6.60 (d, J=8.5, 1H), 5.80 (d, J=8.8, 1H), 5.70 (d, J=21.4, 1H), 5.68 (s, 1H), 5.55 (s, 1H), 5.41 (s, 1H), 4.55 (d, J=4.9, 1H), 4.18 (dt, J=4.6, 1,2, 1H), 2.30-2.22 (m, 1H), 1.90-1.74 (m, 1H), 1.74-1.66 (m, 1H), 1.58 (s, 3H), 1.35 (s, 3H), 1.32-1.24 (m, 4H), 1.08 (s, 3H).
- Preparation of (±)-(5l,l′l)-5-(2,3-epoxy-2,3-dimethylcyclopentyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 96, Structure 3 of Scheme I, where R9═R13═R19═R20═R21═H, R8═R10=fluorine, R6═R15═R17=methyl, R14/R15═—O—, n=0)
- This compound was prepared by epoxidation of Compound 71 (Structure 3 of Scheme I, where R9═R13═R19═R20═R21═H, R8═R10=fluorine, R6═R15═R17=methyl, R14/R16=a bond, n=0) as a solid: 1H NMR (500 MHz, acetone-d6) 7.49 (d, J=8.5, 1H), 7.34 (ddd, J=9.2,1.8, 1.8, 1H), 6.89 (ddd, J=9.5, 2.8, 2.8, 1H), 6.73 (d, J=8.6, 1H), 6.18 (d, J=9.5, 1H), 5.68 (s, 1H), 5.53 (s, 1H), 2.35 (dt, J=9.8, 1.8, 1H), 2.28 (d, J=0.6, 3H), 1.69 (dd, J=13.7, 8.2, 1H), 1.48 (s, 3H), 1.47-1.43 (m, 1H), 1.36 (s, 3H), 1.25 (s, 3H), 1.01 (s, 3H), 0.98-0.92 (m, 1H), 0.78-0.72 (m, 1H).
- Preparation of (±)-(5l,l′u)-5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 97, Structure 3 of Scheme I, where R9═R13═R15═R18═R19═R20═R21═H, R8═R10=fluorine, R6═R7=methyl, R14/R16═—O—, n=1)
- This compound was prepared by epoxidation of Compound 35 (Structure 3 of Scheme I, where R9═R13═R15═R18═R19═R20═R21═H, R8═R10=fluorine, R6═R17=methyl, R14/R16=a bond, n=1) according to a standard procedure as yellow solids: Compound 97, 1H NMR (500 MHz, acetone-d6) 7.57 (d, J=8.5, 1H), 7.35 (ddd, J=9.2,1.8, 1.8, 1H), 6.88 (ddd, J=9.5, 2.8, 2.8, 1H), 6.80 (d, J=8.5, 1H), 5.94 (d, J=10.4, 1H), 5.77 (s, 1H), 5.61 (s, 1H), 2.65 (s, 1H), 2.27 (d, J=0.9, 3H), 2.12-2.06 (m, 1H), 1.86-1.80 (m, 1H), 1.76-1.68 (m, 1H), 1.66-1.58 (m, 1H), 1.46-1.40 (m, 1H), 1.37 (s, 3H), 1.36-1.26 (m, 2H), 1.21 (s, 3H), 1.11 (s, 3H).
- Preparation of (±)-(5l,l′l)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-5H-chromeno[3,4-f]quinolin4-one (Compound 98, Structure 4 of Scheme I, where R4═H, R17=methyl, X═O)
- These compounds were prepared in-a similar fashion as that described in Example 1 general procedure from 3-(dimethylphenylsilyl)-3-methyl-1-cyclohexene (Structure 6 of Scheme I, where R17=methyl, R15═R18═R19=R20═R21═H, n=1) and 7,9-difluoro-1,2,3,4-tetrahydro-5-methoxy-2,2-dimethyl-5H-chromeno[3,4-f]quinolin-4-one (Compound 99). 1H NMR (500 MHz, CDCl3), 7.55 (d, J=8.9, 1H), 7.02-6.95 (m, 1H), 6.70-6.64 (m, 1H), 6.66 (d, J=8.6, 1H), 6.42 (d, J=5.8, 1H), 5.26 (s, 1H), 4.42 (s, 1H), 2.67 (d, J=15.2, 1H), 2.56 (d, J=15.0, 1H), 2.48 (m, 1H), 1.94-1.80 (m, 2H), 1.78-1.66 (m, 2H), 1.44 (s, 3H), 1.37 (s, 3H), 1.32 (s, 3H), 1.42-1.36 (m, 1H), 1.29-1.25 (m, 1H).
- The in vitro activity of selected hPR modulator compounds of the present invention were evaluated utilizing the cotransfection assay, and in standard receptor competitive binding assays, according to the following illustrative Examples.
- Cotransfection Assay
- The function and detailed preparation procedure of the cotransfection assays have been described previously (Pathirana, C. et al., Nonsteroidal Human Progesterone Receptor Modulators from the Marine Alga Cymopolia Barbata. Mol. Pharm. 1995, 47, 630-635). Briefly, the cotransfection assays were carried out in CV-1 cells (African green monkey kidney fibroblasts), which were transiently transfected, by the standard calcium phosphate coprecipitation procedure (Berger, T. S. et al., Interaction of Glucocorticoid Analogues with the Human Glucocorticoid Receptor. J. Steroid Biochem. Mol. Bio. 1992, 41, 733-738) with the Plasmid containing receptor, MTV-LUC reporter, pRS-β-Gal, and filler DNA (Rous sarcoma virus chloramphenicol acetyltransferase). The agonist activity was determined by examining the LUC expression (normalized response) and the efficacy readout was a relative value to the maximal LUC expression produced by progesterone. All the cotransfection experiments were carried out in 96-well plates by automation (Beckman Biomomek automated workstation).
- Receptor Binding Assays
- The preparation of receptor binding assays for hPR-A was described in literature (Pathirana, C. et al., Nonsteroidal Human Progesterone Receptor Modulators from the Marine Alga Cymopolia Barbata. Mol. Pharm. 1995, 47, 630-635.)
- The agonist, antagonist and binding activity assay results of selected progesterone receptor modulator compounds of the present invention and the standard reference compounds on PR are shown in Table 1 below. Efficacy is reported as the percent maximal response observed for each compound relative to the reference agonist and antagonist compounds indicated above. Also reported in Table 1 for each compound is its antagonist potency or IC50 (which is the concentration (nM), required to reduce the maximal response by 50%), and its agonist potency or EC50 (nM), which is the effective concentration that produced 50% of the maximum response.
TABLE 1 Agonist, antagonist and binding activity of progesterone receptor modulator compounds of present invention and the reference agonist compound, progesterone (Prog), and reference antagonist compound, RU486 and ZK299. PR Agonist PR Antagonist PR CV-1 Cells CV-1 Cells Binding Cmpd Efficacy Potency Efficacy Potency Ki No. (%) (nM) (%) (nM) (nM) Prog 100 2.9 na na 3.5 RU486 na na 96 0.18 0.58 ZK299 na na 99 1.6 18 24 168 3.6 na na 6.4 25 86 9.7 na na 6.3 27 68 43 na na 241 28 171 0.9 na na 2.0 34 164 0.5 na na 3.7 35 100 5.4 na na 14 37 na na 50 113 >1000 38 166 0.6 na na 1.9 41 122 10 na na 11 42 27 38 na na 143 44 123 6.7 na na 7.7 45 94 9.1 na na 17 64 na na 80 1900 485 65 na na 59 650 329 71 139 3.4 na na 3.9
na = not active (i.e. efficacy of <20 and potency of >10,000
- The in vivo activity of selected hPR modulator compounds of the present invention were evaluated utilizing the McPhail assay, according to the following illustrative Examples. The Clauberg or McPhail assay is a classic assay utilizing rabbits to measure progestational activity. The reason rabbit is used is because the results observed in rabbit have proved to be a good indicator and predictor of activity in the human. In this assay, immature rabbits are treated initially with estradiol, which induces growth in the uterus. This is followed by treatment with a progestin, which causes a large change in the glandular content of the uterus. It is this change in the glandular component, which is a measure of the progestational activity of a progestin. The measurement of these glandular changes are carried out histologically using stained sections of the uterus. The assay results of the new 5-cycloalkenyl compounds are tabulated in Table 2. The in vivo potency of the progestins is presented as the minimum active dose (MAD) in mg/kg.
TABLE 2 The potency (MAD in mg/kg) of selected 5-cycloalkenyl compounds of present invention in the McPhail assay. Compd # MAD (mg/kg) EC50 (nM) Ki (nM) 24 0.25 3.6 6.4 34 0.25 0.5 3.7 38 0.10 0.6 1.9 71 0.25 3.4 3.9
Pharmacological and Other Applications - The following Example provides illustrative pharmaceutical composition formulations:
- Hard gelatin capsules are prepared using the following ingredients:
Quantity (mg/capsule) COMPOUND 24 10 Starch, dried 100 Magnesium stearate 10 Total 120 mg
The above ingredients are mixed and filled into hard gelatin capsules in 120 mg quantities. - A tablet is prepared using the ingredients below:
Quantity (mg/tablet) COMPOUND 24 10 Cellulose, microcrystalline 200 Silicon dioxide, fumed 10 Stearic acid 10 Total 230 mg - The components are blended and compressed to form tablets each weighing 230 mg. Tablets, each containing 10 mg of active ingredient, are made as follows:
Quantity (mg/tablet) COMPOUND 24 10 Starch 45 Cellulose, microcrystalline 35 Polyvinylpyrrolidone (PVP) 4 (as 10% solution in water) Sodium carboxymethyl starch (SCMS) 4.5 Magnesium stearate 0.5 Talc 1.0 Total 100 mg - The active ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The solution of PVP is mixed with the resultant powders, which are then passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50° C. and passed through a No. 18 mesh U.S. sieve. The SCMS, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.
- Suppositories, each containing 225 mg of active ingredient, may be made as follows:
Quantity (mg/suppository) COMPOUND 24 20 Saturated fatty acid glycerides 2,000 Total 2,020 mg - The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of normal 2 g capacity and allowed to cool.
- An intravenous formulation may be prepared as follows:
Quantity COMPOUND 24 10 mg isotonic saline 1000 mL glycerol 100 mL - The compound is dissolved in the glycerol and then the solution is slowly diluted with isotonic saline. The solution of the above ingredients is then administered intravenously at a rate of 1 mL per minute to a patient.
- The present invention includes any combination of the various species and subgeneric groupings falling within the generic disclosure. This invention therefore includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.
- The scope of the invention is not to be limited by the description of the examples. Modifications and alterations of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention.
- Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims, rather than by the specific examples which have been presented by way of example.
Claims (15)
1. A method of treating an individual having a condition mediated by a progesterone receptor, comprising administering to the individual a pharmaceutically effective amount of a compound represented by formula (I):
wherein:
R1 is selected from the group of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 heteroalkyl, COR11, CO2R11, SO2R11, and CONR11R12;
R2 and R3 each independently is selected from the group consisting of hydrogen, C1-C6 alkyl, and C1-C6 haloalkyl; or
R2 and R3 taken together form a cycloalkyl ring of from three to twelve carbons;
R4 through R7 each independently is selected from the group consisting of hydrogen, F, Cl, Br, CN, OR11, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 heteroalkyl; or
R5 and R7 taken together form a bond; or
R6 and R7 taken together are selected from the group consisting of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;
R8 through R10 each independently is selected from the group consisting of hydrogen, F, Cl, Br, I, NO2, CN, OR11, NR11R12, SR11, COR11, CO2R11, CONR11R12, C1-C8 alkyl, C1-C8 heteroalkyl, C1-C8 haloalkyl, allyl, C2-C8 alkenyl and C2-C8 alkynyl;
R11 and R12 each is independently selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 heteroalkyl, and C1-C4 haloalkyl;
R13 is hydrogen; or
R13 and R14 taken together form a bond and R16 and R18 taken together form a bond when n is 1;
R14 through R20 each independently is selected from the group consisting of hydrogen, F, Cl, Br, OR11, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 heteroalkyl; or
R14 and R15 taken together are selected from the group of methylidene, carbonyl and thiocarbonyl; or
R16 and R17 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene, carbonyl and thiocarbonyl; or
R14 and R16 taken together form a bond or an “—O—” bridge; and
R16 and R18 taken together form a bond when n is 1; or
R16 and R19 taken together form a bond when n is 0;
R21 is hydrogen; or
R21 and R20 taken together form a bond;
n is 0, 1, 2, or 3;
or a pharmaceutically acceptable salt thereof;
with the proviso that R13 and R14 taken together, R16 and R18 taken together and R20 and R21 taken together may not each form a bond;
and thereby treating the individual having a condition mediated by a progesterone receptor.
2. The method of claim 1 , wherein the condition is selected from among dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flushes, mood disorders, meningiomas, hormone-dependent cancers and female osteoporosis.
3. A method of treating an individual having a condition mediated by a progesterone receptor, comprising administering to said individual a pharmaceutically effective amount of a compound represented by formula (II):
wherein:
R2 and R3 each independently is selected from the group of hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl;
R6 is selected from the group of hydrogen, F, Cl, Br, CN, OR11, C1-C4 alkyl, and C1-C4 haloalkyl;
R8 and R10 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR11, NR11R12, SR11, COR11, C1-C4 alkyl, C1-C4 heteroalkyl, C1-C4 haloalkyl, allyl, and C2-C4 alkenyl;
R11 and R12 each is independently selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 heteroalkyl, and C1-C4 haloalkyl;
R13 is hydrogen; or
R13 and R14 taken together form a bond and R16 and R18 taken together form a bond when n is 1;
R14 through R20 each independently is selected from the group consisting of hydrogen, F, Cl, Br, OR11, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 heteroalkyl; or
R14 and R15 taken together are selected from the group of methylidene, carbonyl and thiocarbonyl; or
R16 and R17 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene, carbonyl and thiocarbonyl; or
R14 and R16 taken together form a bond or an “—O—” bridge; and
R16 and R18 taken together form a bond when n is 1; or
R16 and R19 taken together form a bond when n is 0;
R21 is hydrogen; or
R21 and R20 taken together form a bond;
n is 0, 1, 2, or 3;
or a pharmaceutically acceptable salt thereof;
with the proviso that R13 and R14 taken together, R16 and R18 taken together and R20 and R21 taken together may not each form a bond;
and thereby treating the individual having a condition mediated by a progesterone receptor.
4. The method of claim 3 , wherein the condition is selected from among dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flushes, mood disorders, meningiomas, hormone-dependent cancers and female osteoporosis.
5. A method of modulating fertility in an individual, comprising administering to the individual a pharmaceutically effective amount of a compound represented by formula (I):
wherein:
R1 is selected from the group of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 heteroalkyl, COR11, CO2R11, SO2R11, and CONR11R12;
R2 and R3each independently is selected from the group of hydrogen, C1-C6 alkyl, and C1-C6 haloalkyl; or
R2 and R3taken together form a cycloalkyl ring of from three to twelve carbons;
R4 through R7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR11, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 heteroalkyl; or
R5 and R7 taken together form a bond; or
R6 and R7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;
R8 through R10 each independently is selected from the group of hydrogen, F, Cl, Br, I, NO2, CN, OR11, NR11R12, SR11, COR11, CO2R11, CONR11R12, C1-C8 alkyl, C1-C8 heteroalkyl, C1-C8 haloalkyl, allyl, C2-C8 alkenyl and C2-C8 alkynyl;
R11 and R12 each is independently selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 heteroalkyl, and C1-C4 haloalkyl;
R13 is hydrogen; or
R13 and R14 taken together form a bond and R16 and R18 taken together form a bond when n is 1;
R14 through R20 each independently is selected from the group consisting of hydrogen, F, Cl, Br, OR11, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 heteroalkyl; or
R14 and R15 taken together are selected from the group of methylidene, carbonyl and thiocarbonyl; or
R16 and R17 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene, carbonyl and thiocarbonyl; or
R14 and R16 taken together form a bond or an “—O—” bridge; and
R16 and R18 taken together form a bond when n is 1; or
R16 and R19 taken together form a bond when n is 0;
R21 is hydrogen; or
R21 and R20 taken together form a bond;
n is 0, 1, 2, or 3;
or a pharmaceutically acceptable salt thereof;
with the proviso that R13 and R14 taken together, R16 and R18 taken together and R20 and R21 taken together may not each form a bond;
and thereby modulating fertility in the individual.
6. The method of claim 5 , wherein the modulation of fertility is providing contraception to an individual.
7. The method of claim 5 , wherein the modulation of fertility is maintaining pregnancy.
8. A method of treating hormone-dependent cancer, comprising administering to a patient in need thereof an effective amount of a compound of the formula:
wherein:
R1 is selected from the group of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 heteroalkyl, COR11, CO2R11, SO2R11, and CONR11R12;
R2 and R3 each independently is selected from the group of hydrogen, C1-C6 alkyl, and C1-C6 haloalkyl; or
R2 and R3 taken together form a cycloalkyl ring of from three to twelve carbons;
R4 through R7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR11, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 heteroalkyl; or
R5 and R7 taken together form a bond; or
R6 and R7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;
R8 through R10 each independently is selected from the group of hydrogen, F, Cl, Br, I, NO2, CN, OR11, NR11R12, SR11, COR11, CO2R11, CONR11R12, C1-C8 alkyl, C1-C8 heteroalkyl, C1-C8 haloalkyl, allyl, C2-C8 alkenyl and C2-C8 alkynyl;
R11 and R12 each is independently selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 heteroalkyl, and C1-C4 haloalkyl;
R13 is hydrogen; or
R13 and R14 taken together form a bond and R16 and R18 taken together form a bond when n is 1;
R14 through R20 each independently is selected from the group consisting of hydrogen, F, Cl, Br, OR11, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 heteroalkyl; or
R14 and R15 taken together are selected from the group of methylidene, carbonyl and thiocarbonyl; or
R16 and R17 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene, carbonyl and thiocarbonyl; or
R14 and R16 taken together form a bond or an “—O—” bridge; and
R16 and R18 taken together form a bond when n is 1; or
R16 and R19 taken together form a bond when n is 0;
R21 is hydrogen; or
R21 and R20 taken together form a bond;
n is 0, 1, 2, or 3;
or a pharmaceutically acceptable salt thereof;
with the proviso that R13 and R14 taken together, R16 and R18 taken together and R20 and R21 taken together may not each form a bond;
and thereby treating hormone-dependent cancer in the individual.
9. The method of claim 8 , wherein the cancer is selected from the group consisting of ovarian cancer, breast cancer, endometrium cancer and prostate cancer.
10. A method of modulating a progesterone receptor in an individual, comprising administering to the individual a compound of the formula:
wherein:
R1 is selected from the group of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 heteroalkyl, COR11, CO2R11, SO2R11, and CONR11R12;
R2 and R3 each independently is selected from the group of hydrogen, C1-C6 alkyl, and C1-C6 haloalkyl; or
R2 and R3 taken together form a cycloalkyl ring of from three to twelve carbons;
R4 through R7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR11, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 heteroalkyl; or
R5 and R7 taken together form a bond; or
R6 and R7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;
R8 through R10 each independently is selected from the group of hydrogen, F, Cl, Br, I, NO2, CN, OR11, NR11R12, SR11, COR11, CO2R11, CONR11R12, C1-C8 alkyl, C1-C8 heteroalkyl, C1-C8 haloalkyl, allyl, C2-C8 alkenyl and C2-C8 alkynyl;
R11 and R12 each is independently selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 heteroalkyl, and C1-C4 haloalkyl;
R13 is hydrogen; or
R13 and R14 taken together form a bond and R16 and R18 taken together form a bond when n is 1;
R14 through R20 each independently is selected from the group consisting of hydrogen, F, Cl, Br, OR11, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 heteroalkyl; or
R14 and R15 taken together are selected from the group of methylidene, carbonyl and thiocarbonyl; or
R16 and R17 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene, carbonyl and thiocarbonyl; or
R14 and R16 taken together form a bond or an “—O—” bridge; and
R16 and R18 taken together form a bond when n is 1; or
R16 and R19 taken together form a bond when n is 0;
R21 is hydrogen; or
R21 and R20 taken together form a bond;
n is 0, 1, 2, or 3;
or a pharmaceutically acceptable salt thereof;
with the proviso that R13 and R14 taken together, R16 and R18 taken together and R20 and R21 taken together may not each form a bond;
in an amount effective to modulate a progesterone receptor and thereby modulate a progesterone receptor in the individual.
11. The method of claim 10 , wherein the modulation is activation.
12. The method of claim 11 , wherein the compound provides at least 50% maximal activation of the progesterone receptor at a concentration of less than 100 nM.
13. The method of claim 11 , wherein the compound provides at least 50% maximal activation of the progesterone receptor at a concentration of less than 50 nM.
14. The method of claim 11 , wherein the compound provides at least 50% maximal activation of the progesterone receptor at a concentration of less than 20 nM.
15. The method of claim 11 , wherein the compound provides at least 50% maximal activation of the progesterone receptor at a concentration of less than 10 nM.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/411,676 US20060194827A1 (en) | 2002-10-11 | 2006-04-25 | 5-Cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41797502P | 2002-10-11 | 2002-10-11 | |
US10/684,229 US7071205B2 (en) | 2002-10-11 | 2003-10-10 | 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds |
US11/411,676 US20060194827A1 (en) | 2002-10-11 | 2006-04-25 | 5-Cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/684,229 Continuation US7071205B2 (en) | 2002-10-11 | 2003-10-10 | 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060194827A1 true US20060194827A1 (en) | 2006-08-31 |
Family
ID=31994319
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/684,229 Expired - Lifetime US7071205B2 (en) | 2002-10-11 | 2003-10-10 | 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds |
US11/411,676 Abandoned US20060194827A1 (en) | 2002-10-11 | 2006-04-25 | 5-Cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/684,229 Expired - Lifetime US7071205B2 (en) | 2002-10-11 | 2003-10-10 | 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds |
Country Status (11)
Country | Link |
---|---|
US (2) | US7071205B2 (en) |
EP (1) | EP1551845A1 (en) |
JP (1) | JP2006508076A (en) |
AR (1) | AR040782A1 (en) |
AU (1) | AU2003258050A1 (en) |
CA (1) | CA2500758A1 (en) |
CL (1) | CL2003001544A1 (en) |
HK (1) | HK1055058A2 (en) |
MX (1) | MXPA05003721A (en) |
TW (1) | TW200410968A (en) |
WO (1) | WO2004033460A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8193357B2 (en) | 2005-06-17 | 2012-06-05 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
US7026484B2 (en) | 2001-02-23 | 2006-04-11 | Ligand Pharmaceuticals Incorporated | Tricyclic androgen receptor modulator compounds and methods |
CA2501833A1 (en) | 2002-10-11 | 2004-04-22 | Ligand Pharmaceuticals Incorporated | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5h-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds |
HK1055058A2 (en) * | 2002-10-11 | 2003-12-05 | Ligand Pharm Inc | 5-CYCLOALKENYL 5H-CHROMENO[3,4-f]QUINOLINE DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS |
DE20301728U1 (en) | 2002-10-11 | 2004-03-11 | Ligand Pharmaceuticals, Inc., San Diego | 5-substituted-7,9-difluoro-5H-chromeno (3,4-f) quinoline compounds as selective progesterone receptor modulator compounds |
JP4709759B2 (en) * | 2003-08-22 | 2011-06-22 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds |
KR101505382B1 (en) | 2006-03-07 | 2015-03-23 | 지타 쉬로프 | Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation |
WO2020205867A1 (en) | 2019-04-02 | 2020-10-08 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
Citations (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506102A (en) * | 1993-10-28 | 1996-04-09 | Ligand Pharmaceuticals Incorporated | Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription |
US5688808A (en) * | 1994-12-22 | 1997-11-18 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
US5808139A (en) * | 1992-04-21 | 1998-09-15 | Ligand Pharmaceuticals Incorporated | Non-steroid progesterone receptor agonist and antagonist and compounds and methods |
US6001846A (en) * | 1998-02-17 | 1999-12-14 | Ligand Pharmaceuticals Incorporated | Process for the preparation of 1,2-dihydroquinolines |
US6093826A (en) * | 1998-06-08 | 2000-07-25 | Ligand Pharmaceuticals Incorporated | Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines |
US6093825A (en) * | 1998-05-27 | 2000-07-25 | American Home Products | Methods for preparation of 1,2-dihydroquinolines |
US6172241B1 (en) * | 1999-10-15 | 2001-01-09 | Ligand Pharmaceuticals Incorporated | Process for the preparation of 1,2-dihydroquinolines |
US6306851B1 (en) * | 1999-05-04 | 2001-10-23 | American Home Products Corporation | Cyclocarbamate and cyclic amide derivatives |
US6319912B1 (en) * | 1999-05-04 | 2001-11-20 | American Home Products Corporation | Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides |
US6329416B1 (en) * | 1999-05-04 | 2001-12-11 | American Home Products Corporation | Combination regimens using 3,3-substituted indoline derivatives |
US6339098B1 (en) * | 1999-05-04 | 2002-01-15 | American Home Products Corporation | 2,1-benzisothiazoline 2,2-dioxides |
US6355648B1 (en) * | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
US6358947B1 (en) * | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Tetracyclic progesterone receptor modulator compounds and methods |
US6358948B1 (en) * | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
US6369056B1 (en) * | 1999-05-04 | 2002-04-09 | American Home Products Corporation | Cyclic urea and cyclic amide derivatives |
US6380178B1 (en) * | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Cyclic regimens using cyclocarbamate and cyclic amide derivatives |
US6380235B1 (en) * | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Benzimidazolones and analogues |
US6380207B2 (en) * | 1998-02-13 | 2002-04-30 | Abbott Laboratories | Glucocortiocoid-selective antiinflammatory agents |
US6391907B1 (en) * | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
US6399593B1 (en) * | 1999-05-04 | 2002-06-04 | Wyeth | Cyclic regimens using cyclic urea and cyclic amide derivatives |
US6407101B1 (en) * | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
US6417214B1 (en) * | 1999-05-04 | 2002-07-09 | Wyeth | 3,3-substituted indoline derivatives |
US6436929B1 (en) * | 1999-05-04 | 2002-08-20 | Wyeth | Cyclothiocarbamate derivatives as progesterone receptor modulators |
US6444668B1 (en) * | 1999-05-04 | 2002-09-03 | Wyeth | Combination regimens using progesterone receptor modulators |
US6462032B1 (en) * | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
US6498154B1 (en) * | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
US6506766B1 (en) * | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
US6509334B1 (en) * | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
US6696459B1 (en) * | 1994-12-22 | 2004-02-24 | Ligand Pharmaceuticals Inc. | Steroid receptor modulator compounds and methods |
US20040147530A1 (en) * | 2002-10-11 | 2004-07-29 | Lin Zhi | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds |
US20040152717A1 (en) * | 2002-10-11 | 2004-08-05 | Lin Zhi | 5-Substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds |
US6794373B2 (en) * | 1999-05-04 | 2004-09-21 | Wyeth | Contraceptive methods using benzimidazolones |
US7071205B2 (en) * | 2002-10-11 | 2006-07-04 | Ligand Pharmaceuticals Incorporated | 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696103B1 (en) * | 1993-03-19 | 2004-02-24 | Sumitomo Electric Industries, Ltd. | Aluminium nitride ceramics and method for preparing the same |
DK0800519T3 (en) | 1994-12-22 | 2004-03-01 | Ligand Pharm Inc | Steroid receptor modulator compounds and methods |
BR9907788A (en) * | 1998-02-13 | 2001-10-30 | Abbott Lab | Paraglycocorticoid selective anti-inflammatory agents |
JP2002534493A (en) * | 1999-01-16 | 2002-10-15 | チバ スペシャルティ ケミカルズ ウォーター トリートメント リミテッド | Manufacture of acrylic monomers |
CA2371273A1 (en) | 1999-05-04 | 2000-11-09 | Andrew Fensome | Tetracyclic progesterone receptor modulator compounds and methods |
WO2000066560A1 (en) | 1999-05-04 | 2000-11-09 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
AU4682000A (en) | 1999-05-04 | 2000-11-17 | American Home Products Corporation | Contraceptive compositions containing antiprogestinic and progestinic |
EP1173213A1 (en) | 1999-05-04 | 2002-01-23 | American Home Products Corporation | Compositions containing benzimidazolones and progestogens |
WO2000066592A1 (en) | 1999-05-04 | 2000-11-09 | American Home Products Corporation | Cyclic urea and cyclic amide derivatives |
-
2003
- 2003-08-04 HK HK03105597A patent/HK1055058A2/en not_active IP Right Cessation
- 2003-08-04 WO PCT/US2003/024419 patent/WO2004033460A1/en not_active Application Discontinuation
- 2003-08-04 JP JP2004543232A patent/JP2006508076A/en active Pending
- 2003-08-04 CL CL200301544A patent/CL2003001544A1/en unknown
- 2003-08-04 AU AU2003258050A patent/AU2003258050A1/en not_active Abandoned
- 2003-08-04 AR AR20030102795A patent/AR040782A1/en not_active Application Discontinuation
- 2003-08-04 EP EP03808051A patent/EP1551845A1/en not_active Withdrawn
- 2003-08-04 TW TW092121282A patent/TW200410968A/en unknown
- 2003-08-04 CA CA002500758A patent/CA2500758A1/en not_active Abandoned
- 2003-08-04 MX MXPA05003721A patent/MXPA05003721A/en unknown
- 2003-10-10 US US10/684,229 patent/US7071205B2/en not_active Expired - Lifetime
-
2006
- 2006-04-25 US US11/411,676 patent/US20060194827A1/en not_active Abandoned
Patent Citations (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5808139A (en) * | 1992-04-21 | 1998-09-15 | Ligand Pharmaceuticals Incorporated | Non-steroid progesterone receptor agonist and antagonist and compounds and methods |
US5506102A (en) * | 1993-10-28 | 1996-04-09 | Ligand Pharmaceuticals Incorporated | Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription |
US6696459B1 (en) * | 1994-12-22 | 2004-02-24 | Ligand Pharmaceuticals Inc. | Steroid receptor modulator compounds and methods |
US6121450A (en) * | 1994-12-22 | 2000-09-19 | Ligand Pharmaceuticals Incorporated | Intermediates for preparation of steroid receptor modulator compounds |
US5693646A (en) * | 1994-12-22 | 1997-12-02 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
US5696133A (en) * | 1994-12-22 | 1997-12-09 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
US5696130A (en) * | 1994-12-22 | 1997-12-09 | Ligand Pharmaceuticals Incorporated | Tricyclic steroid receptor modulator compounds and methods |
US5696127A (en) * | 1994-12-22 | 1997-12-09 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
US5688810A (en) * | 1994-12-22 | 1997-11-18 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
US5994544A (en) * | 1994-12-22 | 1999-11-30 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
US5688808A (en) * | 1994-12-22 | 1997-11-18 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
US6448405B1 (en) * | 1994-12-22 | 2002-09-10 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
US5693647A (en) * | 1994-12-22 | 1997-12-02 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
US6093821A (en) * | 1994-12-22 | 2000-07-25 | Ligand Pharmaceuticals Incorporated | Process for preparing steroid receptor modulator compounds |
US6380207B2 (en) * | 1998-02-13 | 2002-04-30 | Abbott Laboratories | Glucocortiocoid-selective antiinflammatory agents |
US6506766B1 (en) * | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
US6001846A (en) * | 1998-02-17 | 1999-12-14 | Ligand Pharmaceuticals Incorporated | Process for the preparation of 1,2-dihydroquinolines |
US6093825A (en) * | 1998-05-27 | 2000-07-25 | American Home Products | Methods for preparation of 1,2-dihydroquinolines |
US6268497B1 (en) * | 1998-06-08 | 2001-07-31 | Ligand Pharmaceuticals Incorporated | Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f]quinolines |
US6093826A (en) * | 1998-06-08 | 2000-07-25 | Ligand Pharmaceuticals Incorporated | Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines |
US6407101B1 (en) * | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
US6521657B2 (en) * | 1999-05-04 | 2003-02-18 | Wyeth | Thio-oxindole derivatives |
US6358947B1 (en) * | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Tetracyclic progesterone receptor modulator compounds and methods |
US6358948B1 (en) * | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
US6369056B1 (en) * | 1999-05-04 | 2002-04-09 | American Home Products Corporation | Cyclic urea and cyclic amide derivatives |
US6380178B1 (en) * | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Cyclic regimens using cyclocarbamate and cyclic amide derivatives |
US6380235B1 (en) * | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Benzimidazolones and analogues |
US6339098B1 (en) * | 1999-05-04 | 2002-01-15 | American Home Products Corporation | 2,1-benzisothiazoline 2,2-dioxides |
US6391907B1 (en) * | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
US6399593B1 (en) * | 1999-05-04 | 2002-06-04 | Wyeth | Cyclic regimens using cyclic urea and cyclic amide derivatives |
US6329416B1 (en) * | 1999-05-04 | 2001-12-11 | American Home Products Corporation | Combination regimens using 3,3-substituted indoline derivatives |
US6417214B1 (en) * | 1999-05-04 | 2002-07-09 | Wyeth | 3,3-substituted indoline derivatives |
US6436929B1 (en) * | 1999-05-04 | 2002-08-20 | Wyeth | Cyclothiocarbamate derivatives as progesterone receptor modulators |
US6441019B2 (en) * | 1999-05-04 | 2002-08-27 | Wyeth | Cyclocarbamate and cyclic amide derivatives |
US6444668B1 (en) * | 1999-05-04 | 2002-09-03 | Wyeth | Combination regimens using progesterone receptor modulators |
US6319912B1 (en) * | 1999-05-04 | 2001-11-20 | American Home Products Corporation | Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides |
US6462032B1 (en) * | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
US6498154B1 (en) * | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
US6503939B2 (en) * | 1999-05-04 | 2003-01-07 | Wyeth | Combination regimens using 3,3-substituted indoline derivatives |
US6306851B1 (en) * | 1999-05-04 | 2001-10-23 | American Home Products Corporation | Cyclocarbamate and cyclic amide derivatives |
US6509334B1 (en) * | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
US6355648B1 (en) * | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
US6544970B2 (en) * | 1999-05-04 | 2003-04-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
US6566358B2 (en) * | 1999-05-04 | 2003-05-20 | Wyeth | Cyclocarbamate derivatives as progesterone receptor modulators |
US6841568B2 (en) * | 1999-05-04 | 2005-01-11 | Wyeth | Thio-oxindole derivatives |
US6583145B1 (en) * | 1999-05-04 | 2003-06-24 | Wyeth | Thio-oxindole derivatives |
US6608068B2 (en) * | 1999-05-04 | 2003-08-19 | Wyeth | Indoline derivatives |
US20030216388A1 (en) * | 1999-05-04 | 2003-11-20 | Wyeth | Cyclocarbamate derivatives as progesterone receptor modulators |
US20030220388A1 (en) * | 1999-05-04 | 2003-11-27 | Wyeth | Indoline derivatives |
US20030225109A1 (en) * | 1999-05-04 | 2003-12-04 | Wyeth | Thio-oxindole derivatives |
US6693103B2 (en) * | 1999-05-04 | 2004-02-17 | Wyeth | 1,2,3,4-tetrahydro-2-thioxo-quinolinyl and 1,2,3,4-tetrahydro-2-oxo-quinolinyl derivatives as progesterone receptor modulators |
US6835744B2 (en) * | 1999-05-04 | 2004-12-28 | Wyeth | 3,3-substituted indoline derivatives |
US6713478B2 (en) * | 1999-05-04 | 2004-03-30 | Wyeth | Cyclocarbamate derivatives as progesterone receptor modulators |
US6759408B2 (en) * | 1999-05-04 | 2004-07-06 | Wyeth | Combination regimens using progesterone receptor modulators |
US20040186101A1 (en) * | 1999-05-04 | 2004-09-23 | Wyeth | Cyclocarbamate derivatives as progesterone receptor modulators |
US6794373B2 (en) * | 1999-05-04 | 2004-09-21 | Wyeth | Contraceptive methods using benzimidazolones |
US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
US6172241B1 (en) * | 1999-10-15 | 2001-01-09 | Ligand Pharmaceuticals Incorporated | Process for the preparation of 1,2-dihydroquinolines |
US20040152717A1 (en) * | 2002-10-11 | 2004-08-05 | Lin Zhi | 5-Substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds |
US20040147530A1 (en) * | 2002-10-11 | 2004-07-29 | Lin Zhi | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds |
US7071205B2 (en) * | 2002-10-11 | 2006-07-04 | Ligand Pharmaceuticals Incorporated | 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8193357B2 (en) | 2005-06-17 | 2012-06-05 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds |
Also Published As
Publication number | Publication date |
---|---|
US20040152718A1 (en) | 2004-08-05 |
HK1055058A2 (en) | 2003-12-05 |
CA2500758A1 (en) | 2004-04-22 |
AR040782A1 (en) | 2005-04-20 |
US7071205B2 (en) | 2006-07-04 |
WO2004033460A1 (en) | 2004-04-22 |
CL2003001544A1 (en) | 2005-01-07 |
JP2006508076A (en) | 2006-03-09 |
TW200410968A (en) | 2004-07-01 |
EP1551845A1 (en) | 2005-07-13 |
MXPA05003721A (en) | 2005-06-17 |
AU2003258050A1 (en) | 2004-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060194827A1 (en) | 5-Cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds | |
CN107485612B (en) | Imidazopyridine compounds and uses thereof | |
CA2212856C (en) | Benzopyran-containing compounds and method for their use | |
EP3083603B1 (en) | Benzimidazolyl derivatives as ep4 ligands | |
SK46599A3 (en) | Use of condensated (hetaryl-substituted) 1-benzal-3-pyrazol derivates for treating special diseases of the cardiovascular and the central nervous systems | |
US20060223839A1 (en) | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno-[3,4-f]-quinolines as selective progesterone receptor modulator compounds | |
JPH01301661A (en) | Novel pyridyl derivative | |
MXPA06001751A (en) | 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds. | |
WO2012036287A1 (en) | Novel cortistatin a analog and use thereof | |
JPH0358987A (en) | New compound, preparation thereof, and drug composition containing same | |
WO2019129114A1 (en) | Indoleamine 2,3-dioxygenase inhibitors and use of same in medicine | |
US7163946B2 (en) | 5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds | |
JPH0342275B2 (en) | ||
JPH0339513B2 (en) | ||
JPH0615553B2 (en) | Dihydropyridine-5-phosphonamidic acids | |
WO2017211248A1 (en) | Substituted imidazoquinazoline compound and pharmaceutical composition thereof | |
JP2000507206A (en) | Thieno [2,3-b] pyrazolo [3,4-d] pyridin-3-ones that enhance erythropoiesis | |
JP2022532186A (en) | Amorphous PI3K inhibitor and pharmaceutical composition containing it | |
JPH0453870B2 (en) | ||
AU760232B2 (en) | Benzopyran-containing compounds and method for their use | |
JPH0460478B2 (en) | ||
JPS6229588A (en) | Pyrazolo(4,3-d)pyrimidine derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LIGAND PHARMACEUTICALS, INCORPORATED, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHI, LIN;VAN OEVEREN, CORNELIS ARJAN;PEDRAM, BIJAN;AND OTHERS;REEL/FRAME:017731/0964;SIGNING DATES FROM 20040325 TO 20040409 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |